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1. Introduction 
1.1. Pluripotent stem cells 
 
Over the last two decades, pluripotent stem cells (PSCs) drew the attention of the 
scientific community because of their great promises in regenerative medicine. PSCs 
can give rise to all tissue and cell types of the human body. They are characterized 
by self-renewal, pluripotency and differentiation potential (Jaenisch and Young, 2008; 
Thomson et al., 1998). Self-renewal is defined not only as indefinite proliferation but 
also as the ability to simultaneously maintain pluripotency and inhibit differentiation.  
 
Human (h) PSCs were first gained from the inner cell mass (ICM) of blastocysts 
(Thomson et al., 1998). However, this raised a great ethical debate because it 
involves the destruction of early embryos. Currently, hPSCs can be generated from 
terminally differentiated adult cells by different methods (Figure 1.1), i.e. by nuclear 
transfer to unfertilized oocytes in a process called somatic cell nuclear transfer 
(Tachibana et al., 2013) or by ectopic overexpression of a defined mixture of 
transcription factors in a process called reprogramming (Takahashi, 2007). 
 
To maintain pluripotency, PSCs including embryonic stem cells (ESCs) and induced 
pluripotent stem cells (iPSCs) depend on intricate regulatory networks to 
simultaneously maintain self-renewal potential and to inhibit differentiation. These 
networks are governed by a relatively limited number of key transcription factors 
(TFs), primarily the Yamanaka factors OCT4, SOX2, KLF4 and MYC (Liu et al., 
2008). The ectopic over-expression of solely OSKM is sufficient to reprogram 
terminally differentiated cells back to pluripotency in both human and mouse systems 
(Takahashi and Yamanaka, 2006; Takahashi et al., 2007). 
 
OSKM are involved not only in pluripotency and differentiation regulation in stem 
cells but also in tumorigenesis (Wang et al., 2013; Herreros-Villanueva et al., 2013; 
Akaogi et al., 2009; Lin et al., 2012a). OSKM activity is fine-tuned in stem cells 
transcriptionally as well as by various post-translational modifications (PTMs) such 
as sumoylation (Tahmasebi et al., 2013; Wei et al., 2007), acetylation (Baltus et al., 
2009) and phosphorylation (Van Hoof et al., 2009).  
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Figure 1.1: Derivation and differentiation of hPSCs  
 
hPSCs can be derived from blastocysts of early embryos and cultured in vitro. Alternatively, 
terminally differentiated cells can be reprogrammed by ectopic overexpression of the 
transcription factors OCT4, SOX2, KLF4 and c-MYC (OSKM). In turn, hPSCs can be 
differentiated in vitro to give rise to cells from the three germ layers: Ectoderm, mesoderm 
and endoderm. Figure was adapted and modified from Wang et al., 2014 
 
 
1.2. Role of Akt kinase in stem cells 
Akt kinase is a serine/threonine (S/T) kinase which is highly active in pluripotent stem 
cells (Watanabe et al., 2006) and in numerous tumors (Altomare and Testa, 2005). It 
is well established that Akt kinase promotes pluripotency and self-renewal capacity in 
stem cells through the phosphatidylinositol 3-kinase (PI3K) pathway, suggesting that 
activation of Akt signaling is sufficient to maintain pluripotency in mouse and primate 
stem cells (Watanabe et al., 2006). Furthermore, there is accumulating evidence, 
that Akt directly phosphorylates the TFs Oct4, Sox2 and Klf4 modulating their nuclear 
localization, stability and transcriptional activity (Campbell and Rudnicki, 2013; Jeong 
et al., 2010; Schaefer and Lengerke, 2015). 
Introduction 
13 
In particular, Akt phosphorylates Oct4 at T235 enhancing its transcriptional activity 
and stability (Lin et al., 2012b) and this leads to enhanced apoptotic resistance and 
tumorigenic potential in mouse embryonic carcinoma cells (mECCs). Likewise, Akt 
phosphorylates Sox2 at T118 in mouse embryonic stem cells (mESCs) that results in 
decreased proteasomal degradation of Sox2 protein and enhanced the self-renewal 
capacity of the cells. However, Akt-mediated phosphorylation of Klf4 on T429 (T399 
in mouse Klf4) accelerates its degradation and thereby impairs stemness (Chen et al., 
2013). 
 
The Akt-specific phosphorylation pattern on OSKM with the specific phosphorylation 
sites still needs to be more thoroughly defined. Yet, the available tools exhibit critical 
disadvantages and limitations. One of the widely applied methods to identify the 
specific phosphorylation sites is the co-expression of the kinase and target protein in 
mammalian cells. Different fragments of the protein must be expressed separately 
with the kinase to identify in which fragment the protein is phosphorylated, afterwards, 
the anticipated sites have to be mutated to a non-phosphorylatable residue, namely 
alanine, so the phosphorylation is diminished (Chen et al., 2013). This method is 
usually laborious, time-consuming and not compatible with high-throughput research. 
 
The second common method is the In vitro phosphorylation analyses employing 
recombinant kinases and target proteins. This method provides a faster overview of 
kinase-specific phosphorylation patterns, but to date, all the proteins used for these 
studies are expressed in prokaryotic host cells (mainly E. coli). This system exhibits a 
crucial limitation, because the transcription factors are expressed in inclusion bodies 
and need to be denatured and refolded in vitro (Brumbaugh et al., 2012; Kim et al., 
2009a; Lin et al., 2012b; Thier et al., 2012; Zhou et al., 2009). Recovering of 
overexpressed proteins from inclusion bodies is challenging and usually results in a 
poor yield of natively folded, bioactive proteins (Singh and Panda, 2005). 
 
Therefore, we perceived a necessity to develop a reliable in vitro tool to identify the 
phosphorylation patterns of OSKM particularly by AKT kinase (Figure 1.2). To that 
end, we expressed and purified the transcription factors OCT4, SOX2, KLF4 and 
MYC in Sf9 Insect cells. This eukaryotic expression system is capable of performing 
mammalian-like PTMs (Klenk, 1996) such as phosphorylation which is crucial for the 
TF activity regulation (Cai et al., 2012).  
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Figure 1.2: Simplified experimental overview of the developed in vitro tool 
 
Human OSKM were expressed and purified from Sf9 insect cells. In vitro kinase assay were 
performed using human AKT expressed in Sf9 cells. Subsequently, the proteins were 
subjected to mass spectrometry and the AKT specific phosphorylation pattern was identified. 
 
 
By the application of the Baculovirus Expression Vector System, we produced native, 
highly active recombinant TFs, capable of binding to DNA and similar to their 
mammalian counterparts in terms nuclear transport and intrinsic phosphorylation. 
Furthermore, using mass spectrometry-based phosphoproteomics analysis, we 
identified three novel AKT phosphorylation sites on OCT4, one site on SOX2 and 
four sites on KLF4. We were able to reproduce the phosphorylation sites described in 
previous studies as well.  
Introduction 
15 
1.3. Aurora kinase A in health and disease 
 
Aurora kinases A/B/C are serine/threonine kinases first described in 1995 (Glover et 
al., 1995). They play a critical role in cell cycle and regulate different processes in 
mitosis (Barr and Gergely, 2007). Aurora kinase A (AURKA) gives the trigger for 
mitotic entry and is crucial for centrosome maturation and microtubule spindle 
assembly. However, Aurora kinase B (AURKB) is crucial for chromosome 
segregation and cytokinesis (Sasai et al., 2004). Aurora kinase C (AURKC) share 
many substrates and functions with AURKB and is thought to complement its 
function (Ruchaud et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Structure of human Aurora kinases 
 
Aurora kinases A/B/C harbor a regulatory and a catalytic domain. The start and the end of the 
catalytic domain are indicated as well as the length of the proteins. 
 
Aurora kinases share a C-terminal catalytic domain, A and D boxes but a variable N-
terminal domain (Figure 1.3). The A and D boxes are responsible for the proteasomal 
degradation of Aurora kinases A and B (Fu et al., 2007). The kinase activity of Aurora 
kinases A/B/C depends on autophosphorylation on a central threonine residue in 
their activation loop (T288, T232 and T198 in Aurora kinase A, B and C respectively). 
AURKA is expressed in all phases of cell cycle. However, its activity peaks in the late 
Gap II phase (G2) inducing the G2/M phase transition. Activation of AURKA is 
stimulated by interaction with several mitotic cofactors including Bora, Ajuba, PAK1 
D-box A-box 
Regulatory domain Catalytic domain 
Activation loop 
T288 
D-box A-box 
T232 
D-box 
T198 
403 
344 
306 
132 383 
76 327 
39 290 
Aurora A 
Aurora B 
Aurora C 
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and TPX2 (Figure 1.4). TPX2, a microtubule-associated protein, is the main activator 
of AURKA. In the late G2 phase, it targets AURKA to the mitotic spindle and 
facilitates its autophosphorylation (Kufer et al., 2002). Moreover, it inhibits AURKA 
dephosphorylation by Protein phosphatase 1 (PP1) (Eyers et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Regulators of human Aurora kinase A in cell cycle 
 
AURKA activity in cell cycle is fine-tuned with many positive and negative regulators in a 
temporal manner. The kinases and phosphorylation events are indicated in blue. The 
inhibitory proteins and events are indicated in red. 
 
AURKA initiates mitotic entry by phosphorylation of two important substrates 
CDC25B (Dutertre et al., 2004) and another mitotic kinase PLK1. The later promotes 
AURKA recruitment to the centrosome and provides a platform for interaction with 
other crucial mitotic substrates like Bora and for final activation of the cyclin B-CDK1 
complex (Seki et al., 2008) 
 
The activity of AURKA is tightly regulated in a temporal manner to ensure correct 
progression of cell cycle. During mitosis, PP1 dephosphorylates AURKA at T288 to 
decrease its kinase activity and PP2A dephosphorylates S51 to label AURKA for 
Aurora A 
PAK1 
Bora 
Ajuba 
TPX2 
PP1 
PP2A 
GADD45a 
PLK1 
Aurora A P53 
P
P
P
P P
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proteasomal degradation (Eyers et al., 2003; Walter et al., 2000). Additionally, the 
tumor suppressor P53 inhibits AURKA kinase function through the expression of 
GADD45A, a DNA damage-inducible protein (Shao et al., 2006). At the end of 
mitosis, AURKA gets ubiquitinated by CDH1 activated Anaphase Promoting 
complex/Cyclosome (APC/C CDH1) and degraded by the proteasome (Crane et al., 
2004) 
 
 
 
Figure 1.5: Aurora kinase A localization during mitosis and the main 
interaction partners in tumorigenesis 
 
In the right panel, Aurora kinase A is indicated as red circles through the different phases of 
the cell cycle. Three of the most well known AURKA interaction partners are indicated in the 
left panel. The figure was adapted and modified from Mehra et al., 2013. 
 
AURKA upregulation and/or exaggerated activity has been reported in different 
classes of solid tumors including breast, ovarian, prostate cancers and 
neuroblastoma (Bischoff et al., 1998; Zhou et al., 1998). The oncogenic potential is 
often attributed to spread of AURKA from its normal location near the centrosomes to 
the cytoplasm and even to the nucleus (Tatsuka et al., 2009). Furthermore, 
Increased AURKA expression leads to aneuploidy and genomic instability which is a 
G I 
G I/S 
S phase 
Centrosome 
Nucleus 
G II/M 
Prophase 
Prometaphase 
Metaphase 
Anaphase 
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M phase 
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major stimulus for tumorigenesis (Marumoto et al., 2005). However, the aneuploidy 
caused by AURKA overexpression can trigger the mitotic checkpoints and even 
induce apoptosis (Meraldi et al., 2002). Despite the established evidence that 
AURKA is involved in tumorigenesis, AURKA heterozygosity (deletion of one allele) 
leads to enhanced tumor incidence in mice suggesting its role as a haploinsufficient 
tumor suppressor (Lu et al., 2008). 
 
AURKA interacts with more than 60 tumorigenesis-associated partners including 
NF!B, AKT1, RALA, c-MYC, N-MYC and P53 (Figure 1.5) (Nikonova et al., 2013). 
For instance, AURKA phosphorylates P53 on two serine residues. Phosphorylation 
of S315 leading to its destabilization and subsequently degradation via MDM2 
pathway (Katayama et al., 2004). Moreover, phosphorylation of S215 is reported to 
abrogate P53 transcriptional activity and P53-induced cell cycle arrest (Liu et al., 
2004). Phosphorylation of NFKBIA by AURKA increases NF!B transcriptional activity 
on prosurvival genes (Briassouli et al., 2007). The interaction between c-MYC and 
AURKA was reported to augment the oncogenic potential of both in many solid 
tumors including colon cancer and hepatic cell carcinoma (Lu et al., 2014; Yang et al., 
2010) 
 
However, not all the interactions described in literature are dependent on AURKA’s 
kinase function. There is growing evidence that AURKA has kinase-independent 
functions in mitosis as well as in cancer. Surprisingly, It has been reported that the 
kinase function of Aurora A is not required in the cell division of C. elegans embryos 
(Toya et al., 2011). Moreover, some described oncogenic functions of AURKA are 
kinase-independent. For instance, in neuroblastoma, AURKA stabilizes N-MYC in a 
kinase-independent manner (Otto et al., 2009). 
 
In stem cells, Aurora kinase A role has been a matter of controversy. In a study 
performed by Lee et al., it has been identified as a fundamental kinase for self-
renewal and pluripotency. Knockdown of Aurka in mESCs resulted in complete loss 
of self-renewal and led to differentiation to ectodermal and mesodermal lineages. 
Moreover, Aurka inhibition by the MLN8237 or knockdown reduced the 
reprogramming efficiency of MEFs to iPSCs (Lee et al., 2012a). However, Li and 
Rana in the same year identified Aurka as a barrier to reprogramming. They showed 
that Aurka inhibition by MLN8237 or knockdown greatly enhanced reprogramming 
efficiency (Li and Rana, 2012). 
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Preliminary experiments in our lab pointed to a direct interaction between AURKA 
and the transcription factors OCT4 and c-MYC. We further investigated the role of 
Aurka in mESCs and identified novel kinase-independent effects in regulating Oct4 
and c-Myc. By performing luciferase assays, we found that AURKA enhanced the 
transcriptional activity of both transcription factors in a kinase-independent manner. 
In mESCs, Aurka overexpression stabilized c-Myc protein. However, knockdown of 
Aurka destabilized Oct4. Furthermore, we discovered that MLN8237 has diverse 
effects in mESCs. It destabilized Aurka, Oct4 and c-Myc proteins. Moreover, 
MLN8237 inhibited c-Myc mRNA expression in reprogrammed MEFs resulting in 
reduced reprogramming efficiency. Taken together, we conclude that Aurora kinase 
A is essential in stem cells. However, its kinase function is not the main regulator of 
pluripotency. 
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1.4. Chitosan nanoparticles for OCT4 nuclear 
delivery 
 
The generation of human induced pluripotent stem cells from adult somatic cells 
represents a major advancement in stem cell biology, especially because of their 
many potential applications including patient-specific tissue replacement, drug 
screening and disease modeling (Okita and Yamanaka, 2011; Robinton and Daley, 
2012). As mentioned before, human somatic cells can be reprogrammed to iPSCs by 
the ectopic expression of the four pluripotency-related transcriptional factors OCT4, 
SOX2, KLF4 and c-MYC, also known as the OSKM factors (Takahashi et al., 2007). 
 
In most cases the OSKM factors are introduced into somatic cells via retroviral 
transduction, which however bears the risk of insertional mutagenesis of the 
genome-integrating viruses. Indeed, retroviral vector DNAs can insert at a large 
number of sites in the host genome and promote the expression of oncogenes or 
disrupt tumor suppressor genes, leading to the development of cancer. To address 
this concern, several protocols have been explored to circumvent the integration of 
foreign DNA into the genome. These include the transient expression of 
reprogramming factors using non-integrating adenoviruses, plasmids, RNA, episomal 
vectors or the excision of the transgenes after reprogramming by site-specific 
recombinases or transposases (Kaji et al., 2009; Okita et al., 2010; Sommer et al., 
2010; Stadtfeld et al., 2008; VandenDriessche et al., 2009; Warren et al., 2010; Yu et 
al., 2009). While such approaches reduce the risk of insertional mutagenesis, the use 
of nucleic-acid-free approaches by the direct delivery of reprogramming proteins 
represents presumably the safest methods with respect to future clinical applications 
of iPSCs (Cho et al., 2010). In addition of reducing tumorigenicity, the use of proteins 
also avoids the sustained expression of transgenes after reprogramming. Since the 
transcription factor c-MYC is not only crucial for stemness but also is involved in 
tumor formation, its expression should be restricted to the reprogramming process. 
 
A major hurdle for the intracellular delivery of proteins is their limited ability to cross 
the cell membrane. Small protein transduction domains (PTDs) from proteins (e.g., 
HIV-TAT or Antennaria peptide) can be fused to proteins of interest to facilitate the 
host delivery of reprogramming proteins (Kim et al., 2009a; Nemes et al., 2014; Zhou 
et al., 2009). Nevertheless, reprogramming by PTD-bearing proteins is very slow (#8 
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weeks) and inefficient (#0.001% reprogramming rate) compared to retrovirus-based 
protocols (#0.01% of input cells). The low success of protein-induced stem cell 
generation is presumably caused by the low stability and solubility of recombinant 
reprogramming factors as well as their poor endosomal release. Therefore, further 
developments in protein delivery systems are required to enhance the efficiency of 
cellular reprogramming to iPSCs. 
 
Polymeric nanoparticles (NPs), such as chitosan NPs, offer a more promising 
approach. Apart from their biocompatibility and biodegradability, their ability to 
encapsulate therapeutic proteins into their cores protects proteins from premature 
degradation (Agnihotri et al., 2004; Enríquez de Salamanca et al., 2006; Pan et al., 
2002; Vila et al., 2004). Chitosan [poly(N-acetyl glucosamine)] is a biodegradable 
polysaccharide that can be used to formulate NPs by several methods e.g. by 
ionotropic gelation. The ionotropic gelation method is devoid of organic solvents, and 
the incorporation of a therapeutic protein into the NPs occurs via mild electrostatic 
interactions in aqueous, physiological conditions (Agnihotri et al., 2004). As cationic 
polymers chitosan NPs adhere to the negatively charged cell surface, facilitating their 
cellular uptake by endocytosis (Harush-Frenkel et al., 2007). The presence of 
primary amine groups on the NP surface facilitates endosomal escape via the 
proton-sponge effect (Richard et al., 2013). Moreover, tagging of nuclear localization 
sequences (NLS) to the chitosan NPs allows directing NPs to the cell nucleus 
(Tammam et al., 2015a). 
 
Among the OSKM factors, the transcription factor OCT4 is of particular importance 
for reprogramming, stemness and the self-renewal of stem cells (Radzisheuskaya 
and Silva, 2014). OCT4 is highly expressed in pluripotent cells and becomes 
silenced upon differentiation. The precise expression level of OCT4 determines the 
fate of embryonic stem cells (Radzisheuskaya et al., 2013). DNA binding of OCT4 to 
promoter regions initiates transcription of various genes involved in pluripotency or 
self-renewal, such as NANOG and SOX2 (Jerabek et al., 2014). OCT4 is therefore 
considered a master regulator for the maintenance of pluripotent cells and successful 
reprogramming with OCT4 alone has been shown (Kim et al., 2009b). However, it 
was reported that recombinant OCT4 protein has a limited solubility and stability 
under cell culture conditions (Bosnali and Edenhofer, 2008; Thier et al., 2010). 
Furthermore, recombinant cell-permeant OCT4-TAT fusion proteins show a weak 
endosomal release after cellular uptake, which, in addition to their poor stability, 
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represents another bottleneck for achieving robust reprogramming by protein 
transduction (Bosnali and Edenhofer, 2008; Thier et al., 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Simplified experimental overview of the developed integration-
free reprogramming method 
 
NPs were formulated from chitosan monomers and OCT4 recombinant protein, then tagged 
with NLS. Human dermal fibroblasts were treated with the NPs and analyzed for nuclear 
delivery using FRET analysis and confocal microscopy.  
 
 
Various expression systems are available for recombinant protein production. 
Several groups reported the expression of OCT4 in E. coli or mammalian cells 
(Bosnali and Edenhofer, 2008; Nemes et al., 2014; Thier et al., 2010; Zhang et al., 
2012; Zhou et al., 2009). As mentioned before, bacterially expressed OCT4 is usually 
found in inclusion bodies and needs to be denatured and refolded in vitro. The 
refolding process is cumbersome and results normally in very poor yields of properly 
folded active proteins. On the other hand, OCT4 expressed in mammalian cells can 
be purified in a native state, but production of large quantities of purified and active 
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protein remains challenging and expensive. This limitation might be overcome by the 
baculoviral expression system in Sf9 insect cells, which can provide high yields of 
functional proteins (Singh and Panda, 2005).  
 
In order to develop an integration-free, protein-based reprogramming method, we 
formulated nuclear-targeted chitosan NPs for human OCT4. OCT4 was expressed in 
Sf9 insect cells, evaluated with respect to its activity and nuclear localization and 
encapsulated in chitosan NPs (Figure 1.6). Chitosan NPs were able to considerably 
stabilize the DNA-binding activity of recombinant OCT4 as well as to deliver the 
OCT4 cargo into nuclei of human fibroblasts. Our study therefore demonstrates a 
proof-of-concept for a DNA-free protein transduction system, making chitosan NPs 
as a promising and safe tool for cellular reprogramming and derivation of transgene-
free iPSCs. 
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2. Aim of the study 
 
Stem cells drew a vast attention in the last decades because they hold a great 
potential for regenerative medicine. Stem cells are capable of self-renewal and 
differentiation to almost any cell type in the human body. They possess a complex 
pluripotency network governed by a relatively small number of transcription factors, 
primarily, OCT4, SOX2, KLF4 and c-MYC (OSKM). In stem cells, these factors are 
tightly regulated on the post-translational level, mainly by phosphorylation. Therefore, 
the aim of the first project was to establish an in vitro tool to characterize the post-
translational modifications (PTMs) in OSKM and to identify novel AKT 
phosphorylation sites using recombinant proteins expressed in insect cells.  
 
The second project aimed to explore the role of the oncogene Aurora kinase A 
(Aurka) in stem cells. It has been reported that Aurka regulates the self-renewal and 
differentiation of stem cells through phosphorylation of the tumor suppressor p53 and 
Akt kinase. Moreover, There is a great contradiction in literature about the role of 
Aurka in stem cells and reprogramming. In 2012, Lee et al. defined Aurka as a 
fundamental kinase for self-renewal and pluripotency and showed that Aurka 
inhibition decreased reprogramming efficiency. However, in the same year, Li et al. 
identified Aurka as a barrier to reprogramming and upon Aurka inhibition, 
reprogramming efficiency was enhanced. Moreover, there is accumulating evidence 
about the kinase-independent functions of Aurka in mitosis and cancer. Preliminary 
results in our lab pointed to a direct interaction between Aurka and the pluripotency 
transcription factors c-Myc and Oct4. Therefore, the second project aimed to explore 
the effect of Aurka on the transcriptional activity and stability of c-Myc and Oct4. 
Furthermore, we wanted to disentangle the role of Aurka in reprogramming of MEFs 
to iPSCs. 
 
Reprogramming of somatic cells to pluripotent stem cells circumvents the two major 
problems in stem cells research. Firstly, the ethical burden to kill human embryos to 
extract embryonic stem cells, secondly, the fear of immuno-rejection by allogeneic 
transplantations. Reprogramming is routinely performed by ectopic overexpression of 
OSKM using viral vectors increasing the risk of genetic manipulations by viral 
integrations in the host genome. Therefore, the aim of the third project was to 
establish an integration-free, protein-based reprogramming method using 
biodegradable chitosan nanoparticles (NPs).  
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3. Materials and Methods 
3.1. Materials 
3.1.1. Cell lines 
Cell line Description Provider 
hFib Human dermal fibroblasts Tuebingen University 
Hospital 
 
hFFn Human neonatal foreskin 
fibroblasts 
Tuebingen University 
Hospital 
 
HEK293FT Human embryonic kidney 
cells 
Invitrogen 
 
 
MEF feeder cells Mouse embryonic 
fibroblasts, feeders for 
mESCs 
 
Own production 
mESCs V64 Mouse embryonic stem 
cells 
 
Stemgent 
Sf9 cells Spodoptera frugiperda 
clonal isolation of Sf21 
Invitrogen 
 
3.1.2. Cell culture media 
Culture Media Components 
Feeder MEF medium DMEM High Glucose + Glutamine 
10% FCS  
1% Penicillin/Streptomycin 
 
hFib medium RPMI-1640  
10% FCS  
1% Penicillin/Streptomycin 
 
Infection medium DMEM Knockout (KO) 
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10% Serum replacement,  
1% NEAA 
0.5 mM $-mercaptoethanol 
8 %g/ml protamine sulfate 
 
MEF / HEK293FT medium DMEM High Glucose + Glutamine 
10% FCS  
1% Penicillin/Streptomycin  
 
MEF/ HEK293FT freezing medium  50% MEF/HEK293FT medium  
40% FCS  
10% DMSO  
 
mES Freezing medium 50% mES medium 
40% KO Serum Replacement 
10% DMSO 
 
mES medium DMEM KO 
20% KO Serum Replacement  
1% MEM non-essential amino acids 
1% Penicillin/Streptomycin 
1% L-Glutamine 
0.08 mM ß-Mercaptoethanol 
1000 U/mL LIF (freshly added) 
 
Sf9 medium 
 
Ex-Cell 420 
10% FCS 
1% Penicillin/Streptomycin 
 
siRNA Transfection medium for mESCs DMEM KO 
 
Transfection medium DMEM + Glutamine + 10% FCS 
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3.1.3. Chemicals and reagents 
3.1.3.1. Chemicals 
Reagent Provider 
2-Propanol VWR 
4-Aminoantipyrine-phenol  Acros Organics 
Acrylamide Rothiporese Gel 40 Carl Roth 
Adenosine triphosphate CST 
Ammonium persulfate (APS) Carl Roth 
Ampicillin Carl Roth 
Bovine Serum Albumin (BSA) fraction V Carl Roth 
Bradford reagent Fermentas 
Bromophenol blue Sigma-Aldrich 
BSA-FITC Own production 
BSA-RITC Own production 
Calcium chloride dihydrate Merck 
Chitosan low molecular weight Sigma 
Complete Mini Protease Inhibitor Roche 
Deoxycholic acid sodium salt Sigma-Aldrich 
Disodium phosphate dihydrate Merck 
Dithiothreitol (DTT) Carl Roth 
DMSO NeoLab 
DNA Gel Loading Dye (6x)  Thermo Scientific 
dNTP Mix (100 mM each) Fermentas 
ECL Western Blotting Substrate Promega 
EDTA Carl Roth 
Ethanol VWR 
Fluorescein isothiocyanate (FITC) Thermo Scientific 
Fluorescence-mounting medium Dako 
Glacial acetic acid Carl Roth 
Glycerol AppliChem 
Glycine AppliChem 
HEPES Carl Roth 
Horseradish peroxidase Sigma Aldrich 
Hydrochloric acid (HCl) Carl Roth 
Hydrogen peroxide Carl Roth 
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Isopropanol Merck 
Kanamycin Sigma Aldrich 
KAPA 2G Hot Start Polymerase  KAPA Systems 
Magnesium chloride dihydrate AppliChem 
Methanol Merck 
Midori Green Advance Biozym Scientific 
Monosodium phosphate monohydrate Merck 
Non-fat dried milk Applichem 
Nonidet P-40 AppliChem 
Nuclear localization signal (CPKKKRKV) Bio Basic Canada Inc. 
Nuclease-free water Ambion 
O’GeneRuler 1kb Plus DNA ladder Fermentas 
Paraformaldehyde Carl Roth 
PhosSTOP Phosphatase Inhibitor Roche 
PMSF Merck 
poly(dI-dC) Sigma Aldrich 
ResoLight Dye Roche 
Rhodamine B isothiocyanate (RITC) Sigma Aldrich 
Sodium azide Carl Roth 
Sodium bicarbonate Carl Roth 
Sodium chloride VWR 
Sodium chloride Carl Roth 
Sodium deoxycholate Carl Roth 
Sodium dodecyl sulfate AppliChem 
Sodium hydroxide Carl Roth 
SPDP Pierce Protein Biology Products 
Spectra multicolor board range protein 
ladder 
Thermo Scientific 
TEMED Carl Roth 
Tripolyphosphate Mistral chemicals 
Tris base Applichem 
Triton X-100 Carl Roth 
Tween-20 Merck 
WGA-Alexa Fluor 488 Life Technologies 
WGA-FITC Sigma Aldrich 
 
3.1.3.2. Cell culture reagents 
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Reagent Provider 
Aurora A Inhibitor I Selleckchem 
Cycloheximide Sigma Aldrich 
DharmaFECT 1 Dharmacon 
Dimethyl sulfoxide (DMSO) Sigma Aldrich 
DMEM F12  Invitrogen 
DMEM High Glucose (+ L-Glutamine) Sigma Aldrich 
Dulbecco’s Phosphate Buffered Saline Sigma Aldrich 
Ex-Cell 420  SAFC- Biotechnologies 
Fetal Calf Serum Sigma Aldrich 
Glutamine (100x) Life Technologies (Gibco) 
jetPEI Transfection Reagent Polyplus Transfection 
Knockout DMEM Life Technologies (Gibco) 
Knockout Serum Replacement Gibco 
L-Glutamine (100x) Gibco 
Leukemia inhibitory factor (LIF) Biomol 
MEM Non-essential amino acids Sigma Aldrich 
Mitomycin C Santa Cruz 
PBS PAA 
Penicillin/Streptomycin (100x) Sigma Aldrich 
RPMI-1640  Sigma Aldrich 
Sodium chloride 150 mM  Polyplus Transfection 
Sodium pyruvate Gibco 
ß-Mercaptoethanol Sigma Aldrich 
Trypsin/EDTA Sigma Aldrich 
 
3.1.3.3. Cloning reagents 
Reagent Provider 
Agarose Carl Roth 
Baculogold Bright Linearized DNA  BD Biosciences 
BamH1 Thermo Scientific 
EcoR1 Thermo Scientific 
LB medium Carl Roth 
NEB 5-alpha competent E. coli New England Biolabs 
pAcG2T transfer vector BD Biosciences 
Pfx polymerase Life Technologies 
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PvuII Thermo Scientific 
SOC medium New England Biolabs 
T4 DNA ligase New England Biolabs 
 
3.1.3.4. Laboratory consumables 
Cell culture plates and microplates Greiner bio-one 
Cell scraper Greiner bio-one 
Centricons 10 kD  Merck-Millipore 
Falcon tubes Greiner bio-one 
Floatlyzers spectra/por, MWCO 100KD  Spectrum labs 
Gel blotting paper Whatman 
GSTrap FF 1-mL columns GE Healthcare 
Half Area 96-well microplate Perkin Elmer 
LightCycler® 480 384-well plate, white Roche 
LightCycler® sealing foil Roche 
P F membrane GE Healthcare 
Reaction tubes 1.5, 2.0 mL Eppendorf 
Roti-Spin centrifugal filters (MWCO 
100KD) 
Millipore 
T-flasks Greiner bio-one 
 
3.1.4. Buffers and solutions 
Buffer/solution Components 
WB Running buffer (10x) 250 mM Tris 
1.92 M Glycine 
1% SDS (w/v) 
 
WB Transfer buffer 25 mM Tris 
192 mM Glycine 
20% Methanol (v/v) 
 
TAE buffer 40 mM Tris 
1 mM EDTA pH 8 
0.12% Glacial acetic acid (v/v) 
 
Laemmli buffer (5x) 1 M Tris/HCl pH 6.8 
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3% DTT (w/v) 
40% Glycerol (v/v) 
20% SDS (w/v) 
0.05% Bromophenol blue (w/v) 
 
Lysis buffer (WB) 10 mM Tris/HCl pH 7.5 
300 mM NaCl 
1% Triton X-100 (v/v) 
2 mM MgCl2 
5 mM EDTA pH 8 
2% Protease inhibitors cocktail,  
10% PhosSTOP  (v/v) added freshly 
 
Blocking buffer (WB) TBS-T 
5% Non-Fat dried Milk (w/v) 
 
Blocking buffer (IF) TBS-T 
4% BSA (w/v) 
 
TBS-T (10x) 0.5 M Tris base/HCl pH 7.4 
1.5 M NaCl 
0.05% Tween-20 (v/v) 
 
Kinase assay buffer 25 mM Tris-HCl pH 7.5 
5 mM ß-Glycerophosphate 
2 mM DTT 
0.1 mM Sodium orthovanadate 
10 mM MgCl2 
 
Buffer A (Sf9 nuclear extraction) 10 mM Na-HEPES pH 7.9 
10 mM KCl 
0.1 mM EDTA 
0.1 mM EGTA 
1 mM DTT 
0.5 mM PMSF (added freshly) 
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Buffer B (Sf9 nuclear extraction) 20 mM Na-HEPES pH 7.9 
400 mM KCl 
1 mM EDTA 
1 mM EGTA 
10% Glycerol (v/v) 
1 mM DTT 
Protease inhibitors (added freshly) 
10 nM Aprotinin, 10 %M Leupeptin, 0.5 
%g/mL Pepstatin, 0.5 mM PMSF 
 
RIPA lysis buffer 25 mM Tris-HCl pH 7.6 
150 mM NaCl 
1% NP-40 (w/v) 
1% Sodium deoxycholate (w/v) 
0.1% SDS (w/v) 
 
Glutathione elution buffer 10 mM GSH 
50 mM Tris/HCl pH 8.0 
 
Coomassie staining solution 0.1% Coomassie Brilliant Blue R-250 
(w/v) 
50% Methanol (v/v) 
10% Acetic acid (v/v) 
 
Coomassie destaining solution 10% Acetic acid (v/v) 
10% Isopropanol (v/v) 
10% Methanol (v/v) 
 
Silver staining fixation solution 10% Acetic acid (v/v) 
40% Ethanol (v/v) 
 
Silver staining sensitization solution 500 mM Sodium acetate  
8 mM Sodium thiosulfate x 5 H2O 
40% Ethanol (v/v) 
 
Silver stain 30 mM Silver nitrate 
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Silver staining developing solution 235 mM Sodium carbonate 
50 %L 37% Formaldehyde 
25 %L 10% Sodium thiosulfate x 5 H2O 
Water to 100 mL 
 
EMSA binding buffer (10 x) 100 mM Tris pH 7.5 
500 mM KCl 
10 mM DTT 
 
TBE buffer (10 x) 1M Tris base 
1M Boric acid 
0.02 EDTA 
 
3.1.5. Nucleic acids 
3.1.5.1. EMSA IRDye 700 oligonucleotides 
EMSA oligonucleotides were labeled from 5’ end with phthalocyanine dye IRDye 
700DX (Peng et al., 2006) ("ex: 689 nm; "em 700 nm). Oligonucleotides were 
purchased from Integrated DNA Technologies.  
 
Denotation Sequence (5´to 3´) 
OCT4 forward primer (For.) GCCGAATTTGCATATTTGCATGGCTG 
OCT4 reverse primer (Rev.) CAGCCATGCAAATATGCAAATTCGGC 
SOX2 For. TAGAAACACAATGCCTTTCTCGGC 
SOX2 Rev. GCCGAGAAAGGCATTGTGTTTCTA 
KLF4 For. GTAGGGGGTGTGCCCGCCAGGAGGGGT 
GGGTCTAAGGTGATAGAGCCTTC 
KLF4 Rev. GAAGGCTCTATCACCTTAGACCCACCCCTCCTGG
CGGGCACACCCCCTAC 
c-MYC For. GTGTTAATTGGGAGCACGTGTAGGT C 
c-MYC Rev. ACCTACACGTGCTCCCAATTAACAC 
UTF1 For. CTGAAAGATGAGAGCCCTCATTGTTATGCTAGTG
AAGTGCCAAGCTGA 
UTF1 Rev. TCAGCTTGGCACTTCACTAGCATAACAATGAGGG
CTCTCATCTTTCAG 
 
The DNA-binding sites are written in bold. In the UTF1 enhancer element, the OCT4-
binding site is written in bold italic and the SOX2-binding site in bold. 
3.1.5.2. Primers for qRT-PCR 
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All primers were purchased from Sigma-Aldrich unless otherwise indicated. 
 
Denotation Sequence (5´to 3´) 
Mm-Oct4 For. GCATACTGTGGACCTCAGGTT 
Mm-Oct4 Rev. TCGAAGCGACAGATGGTGGT 
Mm-Sox2 For. TGCACAACTCGGAGATCAGCA 
Mm-Sox2 Rev. CTCCTGCATCATGCTGTAGCT 
Mm-Klf4 For. GTGCCCCGACTAACCGTTG 
Mm-Klf4 Rev. GTCGTTGAACTCCTCGGTCT 
Mm-Aurka For. CTGGATGCTGCAAACGGATAG 
Mm-Aurka Rev. CGCTGGGAGTTAGAAGGACAC 
Mm-Gapdh For. AGGTCGGTGTGAACGGATTTG 
Mm-Gapdh Rev. TGTAGACCATGTAGTTGAGGTCA 
Mm-Actb For. GGCTGTATTCCCCTCCATCG 
Mm-Actb Rev. CCAGTTGGTAACAATGCCATGT 
Hs-AURKA For. GAGGTCCAAAACGTGTTCTCG 
Hs-AURKA Rev. ACAGGATGAGGTACACTGGTTG 
Mm-c-Myc (QuantiTect Primer) Qiagen (Proprietary sequence)  
 
3.1.5.3. Primers for cloning 
Denotation Sequence (5´to 3´) 
pAcG2T For. CGCGGATCCGATTACAAGGATGACGACGATAAG
ATG 
OCT4 Rev. CG GAATTC TCAGTTTGAATGCATGGGAGAGC 
SOX2 Rev. CGGAATTCTCACATGTGTGAGAGGGGCAGT 
KLF4 Rev. CGGAATTCTTAAAAATGTCTCTTCATGTGTAAGG
C 
c-MYC Rev. CGGAATTC TTACGCACAAGAGTTCCGTAGCTGT 
 
3.1.5.4. Plasmids 
Denotation Description Provider 
Ig !E4 luciferase reporter 
(6w-tk Luc) 
Luciferase reporter with 
HSV tk gene promoter 
Schöler Lab MPI Münster 
c-Myc luciferase reporter Luciferase reporter with Qiagen 
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minimal CMV promoter 
and tandem repeats of E-
box sequence 
Octamer luciferase 
reporter  
Luciferase expression 
plasmid with minimal CMV 
promoter and tandem 
repeats of Oct4 
transcriptional response 
element 
Qiagen 
pBABE-AURKA Retroviral expression 
vector for human Aurora A 
kinase 
Addgene 
pBABE-AURKA KD Retroviral expression 
vector for human Aurora A 
kinase-dead mutant 
D274A 
Addgene 
pMX-GFP Retroviral expression 
vector for GFP 
Cell Biolabs 
pMXs-c-MYC Retroviral expression 
vector for human cMyc 
Addgene 
pMXs-hOCT4 Retroviral expression 
vector for human Oct4 
Addgene 
 
3.1.5.5. Small interfering RNA (siRNA) 
Denotation Description Provider 
siNT SMART pool siRNA 
without a specific target 
Dharmacon 
siAurka SMART pool siRNA 
targeting mouse Aurora A 
kinase 
Dharmacon 
 
3.1.6. Commercial kits 
Kit Application Provider 
AKT kinase kit In vitro kinase assay CST 
Cignal Oct4/Myc reporter 
assay Kit 
Tranfection for luciferase 
assay 
Qiagen 
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Coomassie plus  Protein quantification Pierce Biotechnology 
GeneJET Gel Extraction 
Kit  
PCR purification Fermentas 
GeneJET PCR Purification 
Kit 
PCR product purification Fermentas 
GeneJET Plasmid 
Miniprep Kit 
Plasmid isolation Fermentas 
Luciferase assay Kit Luciferase assay Promega 
Pierce BCA Protein Assay 
Kit 
Protein quantification Thermo Scientific 
QuantiTect Reverse 
Transcription Kit 
cDNA synthesis Qiagen 
RedTaq Mastermix for 
colony PCR 
Colony PCR Genaxxon 
RNeasy Mini Kit + 
QIAshredder 
RNA isolation Qiagen 
 
3.1.7. Antibodies 
Specificity Species Provider 
Anti-mouse IgG HRP 
conjugate 
Goat Promega (# W4021) 
Anti-rabbit IgG HRP 
conjugate 
Goat Promega (# W4011) 
c-Myc  Rabbit GeneTex (# GTX61117) 
GAPDH HRP conjugate  Rabbit CST (# 3683) 
GST clone 1E5 Mouse Santa Cruz (#sc-53909) 
Human Aurora kinase A  Mouse Bethyl lab. (#A300-071A) 
Mouse Aurora kinase A  Mouse BD Bioscience (# 610938) 
Oct4  Rabbit CST (# 2840) 
Phospho-AKT substrate 
(RxRxxS/T) 
Rabbit CST (#9614) 
Phospho-Aurora A/B/C  Rabbit CST (#2914) 
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Phospho-Histone H3 Rabbit CST (#9701) 
Vinculin  Rabbit CST (#13901) 
 
3.1.8. Instruments and systems 
Denotation Application Provider 
Biorupture™ UDC200 Sonification Diagenode 
Dounce homogenizer Nuclear extraction Thermo Scientific 
EasyLC nano-HPLC Chromatography Proxeon Biosystems 
Eclipse Ti Confocal icroscopy Nikon 
Epgradient S Master PCR Cycler Eppendorf 
Fusion Software Western blot imaging Peqlab 
FX Vilber Lourmat Western blot imaging Peqlab 
Infinite M200 Reader Spectrophotometry Tecan 
Lambda 12  Spectrophotometry PerkinElmer 
LEO SUPRA 55 Scanning electron 
microscopy 
Carl Zeiss 
LightCycler 480 II qRT-PCR Roche 
LTQ Orbitrap Elite Mass spectrometry Thermo Scientific 
MaxQuant software Proteomic analysis Max Planck Institute of 
Biochemistry, Martinsried 
Mini-Protean Western Blot BioRad 
Mithras LB 940 / MikroWin 
2000 software 
Luciferase assay Berthold technologies 
NanoDrop 1000 Spectrophotometry Peqlab 
Odyssey imaging system EMSA imaging LI-COR Biosciences 
Zetasizer Nano ZS90 Size/charge measurement Malvern Instruments Ltd 
 
  
Materials and Methods 
38 
3.2. Methods 
3.2.1. Cell culture 
3.2.1.1. Sf9 insect cells 
Sf9 insect cells, a clonal isolate of Sf21, were used for recombinant protein 
expression. Sf9 cells were kept at 27°C without CO2 in both adherent and 
suspension cultures. Frozen cells were thawed for 1 min at 37°C and washed once 
with 10 mL fresh insect cell medium. After 5 min centrifugation at 800 rpm at room 
temperature (RT), cells were seeded in T-flasks with a density of 106 cells/cm2. After 
2-3 passages cells were transferred to suspension culture. Sf9 cells were passaged 
every 2-3 days. Briefly, cells were scraped using a rubber cell scraper, pipetted up 
and down 3 times and centrifuged for 5 min at RT at 800 rpm. Cells were 
resuspended in fresh medium and split 1:3 for adherent cell culture with a density of 
0.5 x 106 cells/mL for suspension culture. For protein expression, suspension 
cultures were used in a density of 2 x 106 cells/mL. 
 
3.2.1.2. Mouse embryonic fibroblasts (MEFs) feeder cells 
MEF feeder cells were isolated from BL6 mouse embryos, which were a kind gift 
from Benjamin Schmid (Hertie Institute for Clinical Brain Research, Tuebingen). Cells 
were kept in hypoxic culture conditions (5% O2, 5% CO2, 37°C) and split 1:3 every 3 
days. Briefly, 90% confluent cells were detached using trypsin/EDTA, washed once 
with PBS, centrifuged for 5 min at 800 rpm at RT and finally resuspended in fresh 
MEF medium. To make feeder cells for mES cell cultures, MEFs were mitotically 
inactivated by mitomycin C. Briefly, cells were grown to confluence followed by 
treatment with mitomycin C (10 %g/mL) for 3 h, washed once with PBS. After washing, 
cells were detached using trypsin/EDTA solution and frozen in 80% FCS + 20% 
DMSO with a density of 6 x 106 cells/cryo-vial. Frozen cells were thawed for 1 min at 
37°C and washed once with 10 mL fresh MEF medium. After 5 min centrifugation at 
800 rpm at RT, cells were resuspended and seeded as feeders in a density of 1.5 x 
104 cells/cm2. 
 
3.2.1.3. Human dermal fibroblasts (hFib) feeder cells 
Human primary fibroblasts were isolated from punch biopsies (diameter: 6 mm) of 
the skin (volar forearm) of healthy donors. The biopsies were fragmented and 
transferred into a 6-well plate in hFib medium and incubated at 37°C, 5% CO2 for 10-
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14 days. The cellular outgrowth was detached by trypsin/EDTA and split to a suitable 
plate size. After reaching 80-90% confluence, cells were split 1:3 every 3 days. hFib 
feeder cells were mitotically inactivated by mitomycin C with the same procedure 
mentioned in the previous section. 
 
3.2.1.4. Mouse embryonic stem cells (mESCs) 
mESCs were cultured under normal conditions (37°C, 5% CO2, 20% O2) using mES 
medium. For optimal growth of mESCs, MEFs were used as feeder cell layer. 
However, for qRT-PCR and western blot experiments, mESCs were seeded on hFib 
feeder layer. mESCs were passaged 1:50 to 1:500 every 3 days on feeder-coated 
plates. Briefly, feeder cells were seeded as previously described. Then, mESCs were 
detached using Trypsin/EDTA solution and resuspended in mES medium. To 
separate mESCs from feeder cells, we exploited the fact that feeder cells are bigger 
in size than mESCs. Therefore, the cell suspension was incubated at RT for 30 min 
and the supernatant was used for passaging or seeding for experiments. Cells 
thawing and freezing was performed with a similar procedure as for MEF feeder cells 
with the use of serum replacement instead of FCS in the freezing medium. 
 
3.2.1.5. OSKM and hAURKA/KD retrovirus production 
Retrovirus was produced under biosafety (S2) regulations. HEK293 FT cells were 
transfected in 175 cm2 T-flasks using JetPei transfection reagent according to the 
manufacturer’s instructions. The amounts of plasmids used for virus production were: 
13.5 %g of either pMXs-GFP/Oct4/Sox2/Klf4/c-Myc or pBABE-hAURKA/ D274A (KD) 
+ 12 %g pUMVC + 1.3 %g pCMV-VSV-G. All plasmids were purchased from Addgene. 
The medium of HEK cells was exchanged and the JetPei/DNA mixture was added 
dropwise. Cells were incubated for 72–80 h. Viral supernatants were harvested and 
concentrated with Vivaspin concentrators (Sartorius) at 3000 rpm.  
 
3.2.1.6. Reprogramming of MEFs to iPSCs 
Retroviruses encoding for the four transcription factors OSKM (4F) were produced as 
described in the previous section. The supernatant of a 175cm2 flask was used for 3 
wells in 6-well plates. For MEF transduction, concentrated viral supernatants were 
mixed with 1.5 ml infection medium and added to MEFs. One day after infection, the 
medium was exchanged to mESC medium (with or without MLN8237). After 4 days, 
MEFs were split on feeder MEFs on 10 cm plates. Colonies were counted after on 
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day 14 after infection and the reprogramming was calculated by normalization on the 
4F samples. 
 
3.2.1.7. Transient gene knockdown 
In order to transiently knockdown Aurka in mESCs, small-interfering RNA (siRNA) 
against Aurka was used. SiRNA without specific target (siNT) was used as a control. 
mESCs were seeded on MEFs in 6-well plates at a density of 105 cells/well.  
Transfection was usually performed one day after seeding with a final concentration 
of 50 nM according to Dharmafect1 (DF1) transfection protocol. Briefly, siRNA was 
mixed with DMEM knockout medium for 5 min. DF1 transfection reagent was mixed 
with DMEM knockout medium in a different tube. siRNA mixture was added to DF1 
mixture and incubated for 20 min at RT. The medium was removed from the cultured 
cells and siRNA/DF1 mixture was added to the cells to a final volume of 2 mL with 
serum replacement containing DMEM knockout medium supplemented with LIF. 24 
or 48 h after transfection, knockdown was confirmed by western blot or qRT-PCR. 
 
3.2.1.8. Treatment with kinase inhibitors 
mESCs or HEK293 cells were seeded as described above. 24 h after seeding, the 
medium was exchanged to fresh medium containing the indicated final 
concentrations of the Aurora A kinase inhibitor MLN8237. Cells were harvested 24 h 
after treatment for western blot and qRT-PCR analysis. 
 
3.2.2. Protein expression in Sf9 cells using baculovirus 
3.2.2.1. Cloning of OSKM into pAcG2T baculovirus transfer vector 
The cDNAs of human OSKM were amplified individually using Pfx polymerase and 
flanked with a flag tag and BamH1 site from 5` end and EcoR1 site from 3` end. After 
digestion with FastDigest EcoR1 and BamH1 and ligation with T4 ligase, the DNA 
amplicons were cloned into insect cell transfer vector pAcG2T encoding N-terminal 
GST fusion proteins. Following transformation of competent NEB 5-alpha E. coli, the 
correct cloning of the inserts was verified by restriction analysis using PvuII. 
 
3.2.2.2. Baculovirus production and amplification 
Recombinant baculoviruses were generated through homologous recombination 
using calcium phosphate co-transfection of the recombinant pAcG2T transfer vector 
and Baculogold Bright Linearized DNA including GFP gene according to the 
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manufacturer instructions. Success of homologous recombination was monitored by 
GFP expression. Baculoviruses were amplified to high-titer stocks by infecting Sf9 
suspension cells with multiplicity of infection of 0.5 pfu/cell. 5 days post-infection the 
supernatant was collected by centrifugation at 2000xg and filtered through 0.22 %m 
filter. Virus stocks were stored up to 1 year protected from light. 
 
3.2.2.3. Baculovirus quantification and Sf9 cells infection 
End point dilution assay (EPDA) was performed to quantify the virus. Briefly, Sf9 
cells were seeded in 96-well plates at a density of 2.5 x 104 cell/well. Serial dilutions 
of the virus (10-2 - 10-9) were prepared and 12 wells were infected with each virus 
dilution. 2 days post-infection the number of GFP positive wells was counted. The 
virus titer was calculated by the infectivity calculator developed by Brett D. 
Lindenbach according to Reed and Muench method (Reed and Muench, 1938). Virus 
titer after two rounds of amplification was # 1.5-2 x 108 pfu/mL. For protein production, 
Sf9 cells were infected with MOI of 10 pfu/cell. 
 
3.2.3. Protein purification 
Sf9 cells were harvested 2 days post-infection for SOX2, KLF4 and c-MYC, and 3 
days post-infection for OCT4 at 2500xg for 10 min. OCT4, SOX2 and KLF4 were 
isolated from purified Sf9 cell nuclei. To this end, the cell pellet was washed with 
PBS and resuspended in Buffer A. After incubation on ice for 15 min, cells were 
homogenized with 25 strokes in a Dounce homogenizer. After centrifugation at 
7000xg for 10 min at 4°C, the nuclear pellet was resuspended in 5 pellet volumes of 
Buffer B and incubated for 30 min at 4°C with rotation. For c-MYC, whole cell 
extraction was performed by incubating the cells for 45 min in ice-cold RIPA lysis 
buffer. Both the nuclear and whole cell lysates were centrifuged at 50,000xg for 15 
min at 4°C to remove cellular debris and filtered through a 0.45 %m filter. Protein 
purification was performed using GSTrap FF 1-mL columns coupled to a peristaltic 
pump. The column was equilibrated with 5 column volumes (CV) of PBS before the 
lysates were loaded with a flow-rate of 1 mL/min. After sample application, the 
column was washed with 10 CV PBS and proteins were eluted in 0.5 mL fractions 
with 5 CV glutathione elution buffer at a flow rate of 0.2 mL/min. All steps were 
performed at 4°C. The purified protein was stored in GSH elution buffer + 25% 
glycerol in -80°C. 
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3.2.4. Protein phosphorylation analysis 
3.2.4.1. In vitro kinase assay 
Kinase assays were carried out in kinase buffer in the presence or absence of 200 
µM ATP. 3 %g of the recombinant proteins OSKM and 0.5 %g of active human AKT1 
protein were incubated for 2 h at 30°C.  
 
3.2.4.2. Mass spectrometry and phospho-proteomic analysis 
After performing the kinase assays, proteins were processed for MS analyses as 
described before (Olsen and Macek, 2009) with the following changes: In-solution 
digestion was performed with endoproteinases Lys-C, trypsin or AspN. LC-MS/MS 
analyses were performed on an EasyLC nano-HPLC coupled to an LTQ Orbitrap 
Elite mass spectrometer as described (Franz-Wachtel et al., 2012). For the analyses, 
15 most intense precursor ions were sequentially fragmented in each scan cycle (90 
min, HCD, top15). The MS data of all experiments was processed using default 
parameters of the MaxQuant software version 1.2.2.9 (Cox et al., 2009). Peak lists 
were searched against a human target-decoy database (taxonomy id 9606), 
containing 84946 forward protein sequences and 248 common contaminants, and 
GST-tagged versions of OCT4, SOX2 and KLF4. The following criteria were applied 
for the database search: Endoproteinases Lys-C, trypsin or AspN were defined as 
proteases and two missed cleavages were allowed. Carbamidomethylation of 
cysteine was set as fixed modification; N-terminal acetylation, oxidation of 
methionine, and phosphorylation of serine, threonine and tyrosine were set as 
variable modifications. Initial precursor mass tolerance was set to 7 ppm and 20 ppm 
at the fragment ion level. Identified MS/MS spectra were further processed by 
MaxQuant for statistical validation and quantification of peptides and protein groups. 
A false discovery rate of 1% was set at the peptide, protein and phosphorylation site 
level. 
 
3.2.5. Chitosan nanoparticles (NPs) characterization 
3.2.5.1. NPs formulation, size and charge determination 
Small (S-NPs) and large (L-NPs) chitosan NPs were formulated by the ionotropic 
gelation method using low-molecular weight chitosan (50–190 kD) and 
tripolyphosphate (TPP) as described (Tammam et al., 2015a). NP average 
hydrodynamic diameter and zeta potential were determined using a Zetasizer Nano 
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ZS90. After dilution of the NP suspension with deionized water samples were 
measured in triplicate at 25°C and calculated as means ± SD. 
 
3.2.5.2. Encapsulation efficiency measurement 
Horseradish peroxidase (HRP; ~150 U/mg) was used as a model protein to study 
protein encapsulation. HRP-loaded chitosan NPs were formulated by dissolving HRP 
in TPP solution. To exclude that the NP encapsulation of proteins by inotropic 
gelation did affect protein activity, encapsulation efficiency (EE) was determined 
based on enzyme activity and protein content. For determination of protein EE, L-
NPs were centrifuged at 14000xg for 30 min before un-entrapped protein was 
quantified in the supernatant. S-NPs were first centrifuged in Roti-Spin centrifugal 
filters (molecular weight cut-off 100 kD) for 20 min at 4000xg before the non-
entrapped protein was quantified in the flow-through. EE based on total protein 
content was determined by Coomassie Plus following removal of excess chitosan. 
HRP L-NPs and S-NPs were purified as described above. To 1 mL of L-NP 
supernatant and S-NP flow-through 20 %L of 20% NaOH were added to each tube. 
Tubes were vortexed allowing the remaining chitosan to precipitate. Tubes were then 
centrifuged at 14000xg for 5 min before chitosan-free supernatants were used to 
quantify un-entrapped protein using Coomassie dye. In order to exclude effects of 
NaOH on protein stability, protein calibration curves were prepared in either S-NP 
flow-through or L-NP supernatant and treated with 20 %L of 20% NaOH similar to the 
test solutions. 
 
3.2.5.3. In vitro release analysis 
To determine the ability of S-NPs and L-NPs to release proteins, HRP-loaded NPs 
were purified, reconstituted in 1 mL deionized water and placed in spectra/por float-
A-lyzers (molecular weight cut-off 100 kD). NP-loaded float-A-lyzers were submerged 
in 6 mL PBS and maintained at 37°C in a shaking water bath. At predetermined time 
intervals, 200 %L of the samples were removed, replaced with fresh buffer and 
analyzed for active HRP. Free HRP was used as a control. All samples were 
analyzed in triplicate and results are given as means ± SD. 
 
Activity-based quantification of HRP was performed as described (Trinder, 1969). 
Briefly, 1.5 mL of 1.7 mM of hydrogen peroxide in 0.2 M potassium phosphate buffer 
was mixed with 1.4 mL of 4-aminoantipyrine-phenol solution (2.5 M 4-
aminoantipyrene, 0.17 M phenol). The increase in absorbance at 510 nm was 
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recorded using a UV–Vis spectrophotometer every 30 sec for 5 min upon addition of 
100 %L enzyme-containing test solution (L-NP supernatant or S-NP flow-through). 
Rate of reaction was determined and used to calculate the enzyme concentration 
from an HRP standard calibration curve. 
 
3.2.5.4. NPs tagging with nuclear localization signal (NLS) 
As a classical NLS, the octapeptide CPKKKRKV was used. NLS tagging to NPs was 
performed via N-succinimidyl 3-[2-pyridyldithio]-propionate (SPDP) an SH-NH2 cross-
linker utilizing the N-terminal SH group in the NLS and cationic amines in chitosan. 
S-NPs with low (L-NLS; 0.25 NLS/nm2), intermediate (I-NLS; 0.5 NLS/ nm2) and high 
(H-NLS; 2 NLS/ nm2) NLS density were synthesized. NLS tagging and 
characterization of the modified NPs was performed as detailed previously (Tammam 
et al., 2015b). 
 
3.2.5.5. Cellular uptake quantification 
For NP treatment, human primary fibroblasts were plated in 96-well plates (2x104 
cells/well) and cultured in hFib medium. After 48 h cells were washed with PBS and 
incubated with purified NP-encapsulated BSA-RITC in serum-containing phenol-red 
free RPMI-1640 medium. The non-modified and NLS-modified S-NPs were added to 
the cells at a concentration of 100, 250 and 500 %g/mL. After 24 h, culture 
supernatants were removed and cells were washed twice with PBS. The amount of 
cell-associated NPs was calculated by fluorometry from standard curves as 
described (Tammam et al., 2015b).  
 
Based on the preferential affinity of wheat germ agglutinin (WGA) to chitosan, FITC-
coupled WGA was exploited to distinguish between cell surface-absorbed and 
internalized NPs. In non-permeabilized cells at 4°C, WGA-FITC is not internalized 
and only labels extracellular chitosan NPs, whereas in permeabilized cells at RT 
WGA-FITC can enter the cell and label both surface-bound and internalized chitosan 
NPs. Therefore, fibroblasts were grown in two 96-well plates and loaded with the 
non-modified or NLS-modified S-NPs as described above. After 24 h, cells were 
washed twice with PBS. In the first plate, cells were fixed with 4% paraformaldehyde 
(PFA) for 15 min, washed with PBS, and permeabilized with 0.1% Triton X-100 for 15 
min. After washing cells were incubated with 100 %L of 10 %g/mL WGA-FITC for 15 
min at RT followed by 3 times washing in PBS. In the second plate, cells were 
incubated on ice for 15 min and then directly treated with WGA-FITC for 15 min on 
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ice. After three times washing in PBS, the amount of bound WGA-FITC was 
determined by fluorometry ("ex: 494 nm; "em 518 nm) in both plates as described 
(Tammam et al., 2015a). Results are expressed as mean ± SD from three 
experiments performed in triplicate. 
 
3.2.5.6. Nuclear uptake quantification 
Nuclear uptake was quantified using Förster resonance energy transfer (FRET) 
fluorometry. The nuclear DNA dye Hoechst 33258 and FITC from FITC-coupled BSA 
were used as FRET donor and acceptor, respectively. Formulation and 
encapsulation of BSA-FITC in unmodified and the different versions of NLS-modified 
S-NPs was performed as described above. Fibroblasts were seeded at a density of 
2x104 cells/well in 96-well plates, treated with 250 %g/mL of the NP versions after 48 
h and incubated for another 24 h. After aspiration of the culture supernatants cells, 
cells were stained with Hoechst dye (1.5 %g/mL). Cells were washed 3 times with 
PBS then analyzed by FRET spectroscopy. Three readings were obtained in the 
FRET channel ("ex 366 nm; -"em 518 nm) either for Hoechst-stained and NP-treated 
cells, for NP-treated cells or for Hoechst-stained cells. FRET was determined from 
the increase in FITC emission due to a nuclear co-localization of both dyes. FRET 
efficiency was calculated as described previously(Tammam et al., 2015b).  
 
3.2.5.7. Scanning electron microscopy 
For morphological analysis, a drop of the diluted NP suspension was spread on glass 
slides and subjected to field-emission scanning electron microscopy using a LEO 
SUPRA 55 microscope. Prior to analysis, NP samples were coated with a fine gold 
layer using a gold sputter module. 
3.2.5.8. Confocal laser scanning microscopy 
Human fibroblasts were seeded on coverslips in 24-well plates at a density of 5x105 
cell/well. After 24 h, cells were treated with either 50 %g/mL of OCT4 encapsulated in 
S-NPs or soluble OCT4 and incubated for another 24 h. Following several washes in 
PBS, cells were stained with Hoechst 33258 (1.5 %g/mL) for 5 min, fixed with 4% 
PFA and permeabilized with 0.1% Triton X-100 in PBS. WGA-Alexafluor 488 was 
added to the cells for 15 min at RT. Cells were then washed twice with PBS and 
incubated in blocking buffer (1% BSA in PBS) for 30 min. OCT4 primary antibody 
(1:100) was incubated overnight at 4°C. After three washes in blocking buffer, FITC-
conjugated goat anti-rabbit IgG (1:500) was applied for 1 h at RT. Coverslips were 
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washed in PBS, mounted in fluorescence-mounting medium and examined by 
confocal microscopy. 
 
3.2.6. Luciferase assay 
HEK293 FT cells were seeded in 24-well plates at a density of 5x104 cells/well. 24 h 
after seeding, cells were transfected with the firefly reporter, renilla control and the 
different DNA mixtures OCT4, c-MYC, AURKA or AURKA KD. 48 h after transfection, 
cells were detached by pipetting, transferred to reaction tubes, washed twice with 
PBS and lysed by passive lysis buffer (PLB). Lysis was completed by freezing at -80 
for 20 min. For luciferase measurement, 2.5 %L of the lysates were pipetted in a 
white half-area 96-well plate, 25 %L of luciferase assay substrate (LARII) were 
injected and firefly luminescence was measured by Mithras luminometer. After 1 sec 
delay, 25 %L of Stop & Glow (S&G) were injected and renilla luminescence was 
measured. Firefly luminescence values of each sample were normalized to its renilla 
control. Ratio of firefly/renilla of the test samples was normalized to the ratio of the 
GFP control. 
 
3.2.7. Gene expression analysis 
Total RNA was isolated with the RNeasy Mini Kit according to the manufacturer’s 
instruction and was stored at -80. Routinely, 1 %g of RNA was reverse-transcribed 
using QuantiTect Reverse Transcription Kit with Oligo-dT and a mix of random 
primers according to the manufacturer’s instructions. 
The LightCycler 480 II System was used for qRT-PCR, KAPA2G was used as a 
polymerase and Resolight as a DNA-staining dye. Briefly, for each 384-well reaction, 
the mixture contained the following: 5 %L KAPA2G mix, 0.03 %L Resolight, 1.48 %L 
water, 1 %L primer mix and 5-10 ng of the test cDNA. The PCR program consisted of 
3 phases: 3 min at 95°C followed by 45 cycles of amplification (10 s at 95°C, 10 s at 
60°C, 10 s at 72°C) and finally one cycle for melting curve analysis (5 s at 95°C, 1 
min at 65°C, 97°C). Gapdh and Actb were used for normalization and relative gene 
expression was calculated as 2^(-ddCp) as described before (Livak and Schmittgen, 
2001).  
 
3.2.8. Protein quantification 
BCA protein assay was used for protein quantification. Briefly, serial dilutions of BSA 
(2-0 mg/mL) were prepared in the used lysis buffer. BSA dilutions and the different 
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samples were loaded on a flat-bottom transparent 96-well plate in duplicates. BCA 
reagents A and B were mixed in proportion 50:1 respectively and added to the wells. 
The plate was incubated at 37° C for 30 min and absorbance was measured at 562 
nm. Samples concentrations were calculated using the BSA standard calibration 
curve. For the purified proteins, Bradford assay was used instead of BCA assay 
because GSH interferes with BCA measurement. Briefly, serial dilutions of BSA (2-0 
mg/mL) were prepared in GSH elution buffer. BSA dilutions and the different column 
elutions were loaded on a flat-bottom transparent 96-well plate in duplicates, 
Bradford reagent was added to the wells at RT and absorbance was measured at 
595 nm. Elution concentrations were calculated using the BSA standard curve. 
 
3.2.9. Western blot analysis 
Cells were harvested either by trypsin/EDTA (mESCs, MEFs) or by pipetting 
(HEK293 FT). After washing with PBS, cells were centrifuged for 5 min at 4500 rpm 
at 4°C. PBS was aspirated and a lysis buffer supplemented with 
protease/phosphatase inhibitors cocktail was added. The lysates were incubated for 
30 min on ice. The lysates were sonicated with Bioruptor for 5 min (5 cycles of 10 s 
on, 50 s off), if phospho-antibodies were intended to be used. Furthermore, the 
lysates were centrifuged for 30 min at 14000 rpm at 4°C to remove remaining cellular 
debris.  
 
The protein samples were mixed with 5x Laemmli buffer and boiled for 5 min at 95°C. 
10-20 %g protein were loaded on 10% SDS-PAGE gels, Multicolor Broad Range 
Protein Ladder was used as a protein marker. After running the gels in WB running 
buffer for 1.5 h at 120 V, the proteins were transferred to polyvinylidene fluoride 
(PVDF) membranes in transfer buffer for 1 h at 100V. After transfer, the membranes 
were blocked using 5% milk or 4% BSA in TBS-T. The membranes were 
subsequently incubated in the corresponding primary antibody solution overnight at 
4°C on a roller shaker. After washing 3 times in TBS-T, the membranes were 
incubated in secondary antibody (HRP-conjugate) solutions for 1 h at RT and 
subsequently washed 3 times with TBS-T. For protein bands detection, the 
membranes were incubated in ECL solution for 2 min and then the 
chemiluminescence signal was visualized with the Fusion-FX7 Spectra detection 
system. 
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3.2.10. Coomassie and silver staining 
The recombinant proteins were separated by 10% SDS-PAGE. For Coomassie 
staining, gels were stained for 1 h in staining solution and destained overnight in 
destaining solution. For silver staining, gels were fixed for 30 min, sensitized for 30 
min, and washed three times for 5 min in H2O. After staining for 30 min in the silver 
nitrate stain, gels were washed in H2O and developed in 100 mL of the developing 
solution. 
 
3.2.11. Electrophoretic mobility shift assay (EMSA) 
EMSA was performed using Odyssey® Infrared EMSA Kit according to the 
manufacturer’s instructions. Briefly, the recombinant proteins or the nanoparticles 
were incubated with 1 %L of IRDye® 700 infrared dye-labeled double-stranded 
oligonucleotides, 2 %L of 10x binding buffer, 2.5 mM DTT, 0.25% Tween-20 and 1 %g 
of poly(dI-dC) in a total volume of 20 %L for 30 min at RT in the dark. Samples were 
separated on 4% native polyacrylamide gels in 0.5x Tris-borate-EDTA buffer at 70 
volts for 1 h. The gel was scanned by direct infrared fluorescence detection on the 
Odyssey imaging system. 
 
3.2.12. Statistical analyses 
Unless stated otherwise, data were expressed as mean ± standard deviation (SD) of 
at least three independent experiments. P-values were determined by unpaired, two-
tailed Student's T-Test. 
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4. Results 
4.1. OCT4, SOX2, KLF4 and c-MYC (OSKM) 
expression and purification 
4.1.1. OSKM expression and protein integrity depended on time 
post-infection 
To optimize protein expression, Sf9 cells were infected with different amounts of 
OCT4 baculovirus to different multiplicities of infection: 3, 5 and 10 plaque forming 
unit (pfu)/cell. No difference was observed between the different MOIs. However, the 
time post-infection affected the protein expression significantly. Full-length OCT4 
protein expression increased 72-84 h post-infection, while the lowest expression 
level was observed 60 h post-infection. Three distinct degradation products were 
detected by OCT4 antibody (Figure 4.1). Matrix-assisted laser desorption/ionization 
(MALDI) analysis showed that these degradation products consist of part of the GST 
moiety and the POU-specific DNA binding domain which was still able to bind to DNA 
in EMSA analyses (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: OCT4 expression in Sf9 cells increased with time post-infection 
  
Western blot of Sf9 insect cells infected with baculovirus coding for human OCT4 preceded 
by GST-tag. Virus titer was quantified as number of plaque forming units/ml (pfu/ml). Cells 
were infected with the indicated MOI (pfu/cell) and harvested at the indicated time points. Cell 
pellets were lysed using RIPA buffer and subjected to immunoblotting using OCT4 antibody. 
Closed arrowheads refer to the full-length protein and open arrowheads to the degradation 
products. 
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Figure 4.2: Time post-infection was crucial for SOX2, KLF4 and c-MYC 
protein integrity 
 
Insect cells were infected with baculovirus encoding GST-tagged human SOX2 or KLF4 or c-
MYC and harvested at the indicated time points. Cells were lysed by RIPA buffer and lysates 
were loaded on GST-affinity columns. Proteins were eluted and the elutions were analyzed by 
SDS-PAGE. (A) Coomassie staining of SOX2 elutions (E1: 0-1.5 ml, E2: 1.5-3 ml). (B) 
Coomassie staining of KLF4 elutions (E1: 0-1.5 ml, E2: 1.5-3 ml). (C) Western blot of c-MYC 
elutions by GST antibody. P1: first purification, E2: second purification. Closed arrowheads 
refer to the full-length protein and open arrow heads to the degradation products. 
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SOX2 and KLF4 protein integrity was checked by Coomassie staining. For SOX2, 
full-length protein was most pronounced 46 h post-infection with almost no 
degradation products. However, after 66 h infection degradation started and 3 bands 
were observed # 50 kD. 72 h post-infection, only degradation products were 
observed. The degradation products were analyzed by MALDI and found to be the 
first 120 amino acid of SOX2 protein (Figure 4.2 A). For KLF4 a similar pattern was 
observed. 55 h post-infection, minor degradation products were observed at # 55 and 
40 kD. Degradation products increased after 72 h. 84 h post-infection, no full-length 
protein was observed; only degradation products mostly at # 25 kD (Figure 4.2 B).  
Similarly, GST antibody showed that c-MYC degrades in cell culture if incubated 
longer than 48 h. A ladder of indistinct degradation products was observed 72-96 h 
post-infection (Figure 4.2 C). Moreover, if the lysates were purified two times 
(purification of the column flow-through), a similar degradation pattern is observed. 
To maintain the highest expression and protein integrity levels for all further protein 
expression and purification experiments, OCT4 expressing Sf9 cells were harvested 
84-94 h post-infection. For SOX2, KLF4 and c-MYC, the cells were harvested 48 h 
post-infection. 
 
4.1.2. Recombinant OSKM localized to the nucleus of Sf9 insect 
cells 
A major advantage of the Sf9 baculovirus system is that, unlike bacterial expression 
systems, proteins can be produced in a native form retaining the correct subcellular 
compartmentalization and post-translational modifications. To produce human OSKM 
proteins their cDNAs were cloned into the N-terminal glutathione S-transferase 
(GST) fusion plasmid pAcG2T. After cotransfection of the vector with linearized 
wildtype baculovirus DNA high-titer virus stocks were produced. In first fractionation 
experiments we noticed that OCT4, SOX2 and KLF4 were predominantly localized in 
the nucleus of Sf9 cells, whereas c-MYC was distributed both in cytoplasmic and 
nuclear fractions, as revealed by Coomassie staining and Western blotting (Figure 
4.3 A). For the purification of OCT4, SOX2 and KLF4 we therefore developed a 
single-step nuclear extraction protocol, allowing an easy enrichment of the 
transcription factors by nuclear fractionation, whereas c-MYC was purified from 
whole cell lysates. 
 
To prepare nuclear fractions Sf9 cells were swollen in hypotonic buffer and broken 
up with a Dounce homogenizer. Representative microscopic pictures show the 
successful nuclear extraction after disruption of the cell membrane (Figure 4.3 B). 
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Following lysis of the nuclei for OCT4, SOX2 and KLF4 or of whole cells for c-MYC, 
GST-affinity chromatography was performed. As revealed by silver staining, all 
transcription factors could be purified to near homogeneity (Figure 4.3 C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Nuclear extraction and purification of OSKM 
 
(A) Upper panel shows Coomassie staining and lower panel shows western blot of 
cytoplasmic (C) and nuclear (N) fractions of Sf9 cells infected with baculoviruses encoding 
O/S/K/M. Sf9 cells were harvested 2 days post-infection for SKM and 3 days post-infection for 
O. (B) Microscopic pictures of Sf9 cells before (left) and after (right) cell membrane disruption 
by dounce homogenization (200x). N: nucleus. (C) Purified OSKM proteins by GST affinity 
chromatography after nuclear extraction (for OSK) and total cell lysis (for M). The full-length 
proteins are marked with a close arrowhead, and the 27 kD GST fragment of the fusion 
proteins with an open arrowhead.  
 
Purified KLF4 showed minor protein bands at 50 and 70 kD, which were recognized 
by the KLF4 antibody and, as revealed by MALDI analysis, represented fragments of 
the transcription factor (data not shown). In addition, a minor GST band was found at 
27 kD, which was most pronounced for c-MYC, presumably due to its purification 
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from cell lysates (Figure 4.3 C). Importantly, from Sf9 suspension cultures 
considerable protein yields of the transcription factors could be obtained: i.e. OCT4: 
6.1 mg/l; SOX2: 1.5 mg/l; c-MYC: 2.8 mg/l and KLF4: 3.8 mg/l. 
 
4.1.3. Recombinant OSKM bound to their consensus DNA binding 
sites 
We next tested the DNA-binding activity of the purified factors using electrophoretic 
mobility shift assays (EMSAs) with different DNA consensus motifs (Figure 4.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: In vitro DNA binding analysis of OSKM by electrophoretic 
mobility shift assay (EMSA) 
 
The DNA-binding activity of OCT4 was analyzed using oligonucleotides containing the OCT4 
1W consensus motif or UTF1 enhancer sequence. SOX2 DNA binding was analyzed using 
oligonucleotides containing the SOX2 consensus motif or the UTF1 enhancer sequence. 
Similarly, the DNA-binding activity of KLF4 and c-MYC was tested with oligonucleotides 
containing the DNA consensus sequences of the transcription factors. Bovine serum albumin 
(BSA) was used as a negative control. The closed arrowheads indicate the specific protein-
DNA complexes and the open arrowheads the unbound oligonucleotides. 
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Even a small amount (75 ng) of recombinant OCT4 was sufficient to reveal strong 
DNA binding to an octamer-binding site from the Ig heavy chain enhancer (1W motif). 
A slightly weaker DNA binding of OCT4 was detected to the OCT4-binding site from 
the enhancer of undifferentiated embryonic cell transcription factor 1 (UTF1), which 
contains an additional adjacent SOX2-binding site (Figure 4.4). In addition, DNA 
binding of recombinant SOX2 could be demonstrated to the classical DNA 
consensus site present in the miR-302 promoter as well as to the UTF1 site (Boyer et 
al., 2005). Moreover, KLF4 bound efficiently to the typical DNA consensus sequence 
of the Nanog promoter. DNA binding of recombinant c-MYC to the classical E-box 
element was somewhat weaker but clearly detectable. For all transcription factors 
DNA-binding was abolished by competition with unlabeled oligonucleotides (data not 
shown). These results therefore suggest that recombinant OSKM factors retain not 
only their typical nuclear localization, but also their DNA-binding activity. 
 
4.2. Identification of novel AKT phosphorylation 
sites in OSK 
In order to investigate AKT phosphorylation sites of the different transcription factors, 
we incubated all four OSKM factors with active baculovirus-derived recombinant 
AKT1 in an in vitro kinase assay. Subsequent immunoblotting of the reactions 
mixtures with an anti–phospho-(Ser/Thr) AKT substrate antibody, which recognizes 
AKT phosphorylation motif sequences, revealed that OCT4, SOX2 and KLF4 were 
efficiently phosphorylated by AKT (Figure 4.5 A). OCT4 showed several degradation 
products, which were strongly phosphorylated by AKT, whereas no phosphorylation 
of c-MYC could be detected.  
 
To identify the AKT phosphorylation sites of the different transcription factors we 
subjected in vitro phosphorylated as well as the control OSKM factors to mass 
spectrometry (MS)-based phosphoproteomic analysis. As expected, we identified 
several intrinsic phosphorylation sites on OCT4 and KLF4 that were phosphorylated 
in the absence of ATP, indicating that the proteins were modified by the intrinsic 
phosphorylation machinery of Sf9 cells. Most phosphorylation sites however were 
dependent on AKT. A representative spectrum of phosphorylation at of OCT4 at 
T225 is shown in Figure 4.5 B. 
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Figure 4.5: OCT4, SOX2 and KLF4, but not c-MYC were phosphorylated by 
AKT in vitro  
 
(A) In vitro kinase assay: The purified OSKM factors were incubated with active AKT1 protein 
in the absence or presence of ATP, and immunoblotted with the indicated antibodies. (B) 
Representative mass spectrum demonstrating AKT-mediated phosphorylation of OCT4 at 
T225 following digestion with LysC. 
 
As published previously (Lin et al., 2012b) OCT4 was found to be further 
phosphorylated by AKT at T235. Importantly, our phosphoproteomic analysis 
identified four further unreported sites in OCT4 that were phosphorylated by AKT, 
namely, S136, T159, T225 and S236 (Figure 4.6). In addition to OCT4, we found that 
AKT phosphorylated SOX2 at S83, which has been also yet not described. KLF4 was 
phosphorylated by AKT at five different sites: the already known residue T429, which 
is homologous to T399 in mouse (Chen et al., 2013), and four further novel sites, 
namely, S19, T33, S234 and S326 (Figure 4.6). 
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Figure 4.6: Novel AKT phosphorylation sites identified in OCT4, SOX2 and 
KLF4   
 
The scheme shows the novel and previously reported AKT phosphorylation sites with the 
functional domains of OCT4, SOX2 and KLF4. OCT4 contains POU-specific and 
homeodomain (HD) DNA-binding domains as well as transactivation domains located at the 
N-terminus (N-TAD) and C-terminus (C-TAD). SOX2 has a high mobility group (HMG) DNA-
binding domain and a transactivation domain (TAD). KLF4 contains a single N-terminal TAD, 
a central proline-rich region (PR) and three zinc-finger (ZF) DNA-binding domains. NLS 
marks the nuclear localization sequences of the transcription factors. 
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4.3. Aurora kinase A regulated c-Myc and Oct4 in a 
kinase-independent manner in stem cells 
4.3.1. c-MYC and OCT4 were identified as AURKA substrates 
Aurora kinase A (Aurka) plays an important role in maintenance of pluripotency and 
self-renewal in stem cells. It has been reported that Aurka protein expression 
correlated with the expression of the core transcription factors Oct4, Sox2 and Nanog 
in mouse embryonic stem cells (Lee et al., 2012a). Moreover, upon knockdown of 
Aurka, Oct4 is downregulated and mES cells started to differentiate into mesodermal 
and ectodermal germ layers. However, the exact regulation mechanism was poorly 
described. Therefore, we investigated whether there is a direct interaction between 
Aurka and the pluripotency transcription factors, especially, Oct4 and c-Myc.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Putative AURKA phosphorylation sites on c-MYC and OCT4 
 
The scheme shows predicted putative AURKA phosphorylation sites with the functional 
domains of c-MYC and OCT4. c-MYC contains a transactivation domain (TAD), basic region 
(BR), Helix-loop-helix-leucine zipper (HLH-LZ) and the MYC boxes (I, II, IIIa, IIIb, IV). OCT4 
contains POU-specific and homeodomain (HD) DNA-binding domains as well as 
transactivation domains located at the N-terminus (N-TAD) and C-terminus (C-TAD). The full-
length of the proteins is indicated as number of amino acids (aa). Serine and threonine are 
referred to as S and T respectively. Prediction was performed using GPS 3.0 phosphorylation 
prediction software. 
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To that end, we performed an in silico analysis of AURKA putative phosphorylation 
sites on human c-MYC and OCT4 using GPS phosphorylation prediction software. 
With the highest threshold set, putative phosphorylation sites were identified on c-
MYC and OCT4. AURKA was predicted to phosphorylate c-MYC on one single site, 
namely, S348, which is located between the fourth MYC box and the basic region of 
c-MYC (Figure 4.7 upper panel). OCT4 had five putative phosphorylation sites, 
namely, T159, S236, S288, S289 and S290 (Figure 4.7 lower panel). These 
phosphorylation sites are located on three domains on the OCT4 protein. T159 is 
located in the POU-specific DNA binding domain, S236 is located in the 
homeodomain (HD) directly next to the nuclear localization sequence (NLS). 
Moreover, S288, S289 and S290 are located in the spacer between the HD domain 
and the C-terminal transactivation domain (C-TAD). These results pointed that there 
might be a kinase-dependent interaction between AURKA and the transcription 
factors c-MYC and OCT4. 
 
4.3.2. AURKA increased the transcriptional activity of c-MYC and 
OCT4 in a kinase-independent manner 
In order to investigate the in vivo interaction between AURKA on one side and c-
MYC and OCT4 on the other side and whether the interaction is kinase-dependent or 
not, transcriptional analyses of these transcription factors were performed using 
luciferase assays. Human AURKA gene or the kinase-dead mutant (KD) was 
overexpressed in HEK293 FT cells in single transfection or in co-transfection with c-
MYC or OCT4 or both. The KD mutant of AURKA was prepared by mutating the 
aspartic acid residue at the position 274 to alanine (D274A) in the DFG domain of the 
kinase rendering the kinase catalytically inactive (Crane et al., 2004). 
 
The used luciferase reporter, Ig %E4, was first described in 1990 (Schöler et al., 
1990). It encodes for firefly luciferase gene under control of thymidine kinase (tk) 
promoter and tandem repeats of %E4 region of the immunoglobulin heavy chain gene 
enhancer (Ig %E4). It harbors a non-canonical E-box sequence CACCTG and an 
Octamer binding site ATTTGCAT (Figure 4.8 A). Luciferase assays were conducted 
in HEK293 FT after transfection of the previously described firefly luciferase reporter 
and the indicated DNA (Figure 4.8. B). A constitutively expressing renilla luciferase 
construct with tk promoter was used as internal control for normalizing transfection 
efficiencies and monitoring cell viability.   
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Figure 4.8:  AURKA increased c-MYC/OCT4 transcriptional activity on 
Immunoglobulin heavy chain enhancer (Ig !E4) 
 
(A) Mouse immunoglobulin (Ig) heavy chain gene: Variable (V), Diversity (D) and Joining (J) 
segments are followed by the enhancer gene (E) which contains in its % E4 region a non-
canonical E-box and an octamer motif (written in red). (B) Luciferase assay in HEK293 FT 
cells upon overexpression of c-MYC, OCT4, AURKA or AURKA kinase dead mutant (KD) 
using a firefly reporter coding for %E4 of the Ig heavy chain enhancer. Cells were transfected 
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with the indicated DNA, %E4 firefly reporter and a constitutively expressing renilla construct as 
a transfection control. Cells were harvested 48 h after transfection. Luminescence values 
were normalized on renilla and GFP controls (relative luciferase activity). n=3, results are 
expressed as mean + SD. * p< 0.05, ** p< 0.01. 
 
AURKA overexpression activated the reporter in the absence of ectopically 
expressed c-MYC and OCT4. Surprisingly, overexpression of the inactive kinase 
AURKA KD showed the same effect. c-MYC reduced the relative luciferase signal 
which was restored by overexpression of AURKA or AURKA KD. OCT4 
overexpression increased the relative luciferase activity and co-expression of 
AURKA or AURKA KD increased the signal even more. Adding c-MYC repressed the 
reporter signal in all combinations (Figure 4.8 B). The KD mutant was confirmed to 
be catalytically inactive by western blot. Successful overexpression of the genes was 
confirmed by western blot (Figure 4.9 A). Upon overexpression of the KD mutant, 
less autophosphorylation was observed by using phospho(p)-AURKA antibody 
(Figure 4.9 B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Confirmation of successful overexpression of AURKA/KD, c-MYC 
and OCT4 
 
(A-B) Western blot of HEK293 FT cells transfected with the indicated DNA. Cells were 
harvested 48h after transfection, lysed and subjected to immunoblotting using the indicated 
antibodies. 
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4.3.3. Aurora kinase A regulated c-Myc and Oct4 protein stability 
and mRNA expression in mESCs 
To disentangle the regulatory networks of Aurka in mESCs, we used different 
approaches. Initially, we infected the cells with retroviruses encoding human AURKA 
or AURKA KD. Amino acid sequence alignment showed 84% identity match between 
mouse and human AURKA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10:  AURKA increased the protein levels of c-Myc in mESCs 
 
 
(A) Western blot of mESCs infected with retroviruses encoding AURKA or AURKA KD. (B) 
Western blot of Aurka knockdown in mESCs. Cells were transfected with small interfering 
RNA (siRNA) against no target (siNT) or against Aurka. Cells were harvested 48 h after 
transfection, lysed and immunoblotted against the indicated antibodies. 
 
Remarkably, overexpression of AURKA led to higher levels of c-Myc protein. The 
same effect was noticed upon overexpression of the KD mutant. The levels of mouse 
endogenous Aurka did not change upon overexpression of the human genes AURKA 
or AURKA KD, neither did Oct4 levels (Figure 4.10 A). Subsequently, we transiently 
knocked down Aurka using small interfering RNA (siRNA). Knockdown was efficient 
and western blot showed #80% reduction on Aurka protein level compared to the 
control (Fusion software, Peqlab). On protein level, Aurka knockdown destabilized 
Oct4 protein. However, no change was noticed in c-Myc levels (Figure 4.10 B). 
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4.3.4. Aurora kinase A inhibitor, MLN8237, modulated the protein 
and mRNA levels of c-Myc and Oct4 in mESCs 
MLN8237 is a selective Aurora kinase A inhibitor, which has been described to have 
diverse effects on Aurora kinase A and its interaction partners in stem cells (Li and 
Rana, 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: MLN8237 decreased Aurka, c-Myc and Oct4 protein levels in 
mESCs 
 
Western blot of mESCs treated with the indicated concentrations of MLN8237. Cells were 
treated 24 h after seeding. 24 and 48 h after inhibitor treatment, the cells were harvested, 
lysed, sonicated and subjected to immunoblotting using the indicated antibodies. Vinculin was 
used as a reference protein in this experiment. 
 
We performed an extensive study on the effect of MLN8237 in mESCs. 
Concentrations ranging from 0.01 to 10 %M were tested. After 24 h of treatment, low 
concentrations of MLN8237 (0.01-0.1 %M) led to higher Aurka protein levels as 
analyzed by western blot. The same effect was noticed for the activated 
phosphorylated form of Aurka (p-Aurka) as well. Remarkably, c-Myc levels correlated 
with Aurka levels. After 48 h, Aurka, c-Myc and Oct4 protein levels returned to the 
basal level (Figure 4.11). 
 
Higher concentrations of MLN8237 (0.25-1 %M) led to lower protein levels of Aurka, 
c-Myc and Oct4 and 10 %M of MLN8237 caused complete abrogation of Aurka, p-
Aurka, c-Myc and Oct4 protein bands 24 h after treatment. After 48 h, in the cells 
treated with 10 %M, Aurka and p-Aurka bands were restored to the basal level. 
However, c-Myc and Oct4 bands remained downregulated (Figure 4.11). 
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Figure 4.12:  MLN8237 activated the transcription of Aurka, c-Myc and Oct4 
mRNA in mESCs 
 
mRNA expression analysis of mESCs treated with the indicated concentrations of MLN8237. 
Cells were treated 24 h after seeding. 24 and 48 h after inhibitor treatment, cells were 
harvested, lysed and RNA was isolated, reverse transcribed and subjected to qRT-PCR using 
the following primers:(A) Aurka, (B) Myc and (C) Oct4. n=3, results are normalized to the 
geometric mean of Gapdh and Actb and to DMSO control (0 %M) and expressed as mean + 
SD. * p< 0.05, ** p< 0.01. 
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mRNA expression levels of Aurka, c-Myc and Oct4 were analyzed after treatment 
with the same concentrations of MLN8237 (0.01-10 %M). MLN8237 increased Aurka 
expression in a concentration-dependent manner 24 h after treatment. The same 
effect was observed 48 h after treatment with the exception that in the cells treated 
with 10 %M concentration, Aurka level returned to the basal level (Figure 4.12 A). No 
significant changes were observed in c-Myc mRNA levels 24 h after treatment. 
However, after 48 h, higher concentrations of MLN8237 (1-10 %M) greatly activated 
its expression (Figure 4.12 B). MLN8237 slightly increased the expression of Oct4 
but no concentration dependence was observed (Figure 4.12 C). 
 
4.3.5. MLN8237 reduced the reprogramming efficiency of MEFs 
c-Myc and Oct4 play a crucial role in reprogramming of MEFs to iPSCs and any 
changes in their regulation can alter the reprogramming efficiency (Takahashi and 
Yamanaka, 2006) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: MLN8237 reduced the reprogramming efficiency of MEFs infected 
with the four factors OSKM (4F) 
 
(A) Reprogramming efficiency of MEFs to iPSCs. MEFs were transduced with the 
retroviruses encoding for the indicated genes. MEFs were treated with MLN8237 24 h after 
transduction. Colonies were counted 14 days after infection and the results were normalized 
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on the number of colonies of the cells infected with the 4F and expressed as the relative 
reprogramming percentage. Results from triplicates were expressed as mean + SD, * p< 0.05. 
(B) Microscopic pictures of iPSCs generated from the reprogrammed MEFs. Bright field (BF) 
are shown in the upper panel and the alkaline phosphatase staining (AP) is shown in the 
lower panel (Magnification 200X). (C-E) mRNA expression analysis of the infected MEFs 4, 7 
and 14 days after infection (D4, D7 and D14). Cells were harvested at the indicated time 
points, lysed and RNA was isolated, reverse transcribed and subjected to qRT-PCR analysis 
using the following primers: (C) c-Myc and (D) Oct4 and (E) Nanog. Results from triplicates 
were normalized to the geometric mean of Alas1/Actb and to D4 samples and expressed as 
mean ± SD. * p< 0.05. 
 
Therefore, we tested the effect of AURKA overexpression and inhibition on the 
reprogramming process of MEFs infected with the 4F. AURKA or AURKA 
overexpression did not cause significant change in the reprogramming efficiency 
(Figure 4.13 A). Furthermore, the colonies from MEFs infected with the 4F together 
with AURKA or AURKA KD showed sharp borders and positive alkaline phosphatase 
staining indicating a fully reprogrammed state (Figure 4.13 B) 
 
The use of MLN8237 in reprogramming has been a matter of debate in the field of 
reprogramming. Li and Rana reported that MLN8237 enhances the reprogramming 
efficiency of MEFs due to inhibition of Gsk3-$ in an Akt-dependent pathway (Li and 
Rana, 2012). However, Lee et al. reported in the same year that MLN8237 reduced 
the reprogramming efficiency in a p53-dependent pathway (Lee et al., 2012a).  
 
Consistent with Lee et al., we found that Aurka inhibition with MLN8237 reduced the 
reprogramming efficiency significantly (Figure 4.13 A). We explored the mRNA 
expression of three important genes during the reprogramming process, namely, c-
Myc, Oct4 and Nanog. Moreover, we tracked the gene expression of these three 
genes over 14 days. In the 4F-infected MEFs, the expression of Oct4 and Nanog 
increased from day 4 to day 14 confirming a successful reprogramming. MLN8234 
treatment reduced the expression of c-Myc and to a lesser extent the expression of 
Oct4. However, the expression of Nanog did not change upon MLN8237 treatment 
(Figure 4.11 C, D and E). 
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4.4. Biodegradable chitosan nanoparticles for 
OCT4 nuclear delivery 
4.4.1. Small and large nanoparticles (S and L-NPs) showed 
homogeneous size and charge distribution 
Using the ionotropic gelation method, we formulated two types of chitosan NPs as 
described previously (Tammam et al., 2015a). Scanning electron microscopy 
revealed that the generated chitosan NPs were spherical with no apparent 
aggregation (Figure 4.14).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: Small and large nanoparticles (S and L-NPs) exhibited 
homogeneous size distribution 
 
Scanning electron micrographs from S-NPs (left) and L-NPs (right). Bars = 200 nm.  
 
The average hydrodynamic diameter of S-NPs and L-NPs was 25 nm and 150 nm, 
respectively. Both NPs had a positive zeta potential which was higher in L-NPs 
compared to S-NPs (Table 1). The encapsulation of HRP did not significantly change 
the hydrodynamic diameter of the NPs. Neither did it affect HRP activity, since 
encapsulation efficiency (EE) determined by either protein content or enzyme activity 
did not significantly differ (Table 1) 
 
Table 1: Characterization of chitosan S-NPs and L-NPs 
 
NP Cargo HD 
(nm) 
ZP  
(mV) 
EE% 
(% Activity) 
EE 
(% Protein) 
S-NP w/o 25 ± 2 35 ± 2 -,-  -,- 
HRP 26 ± 2 22 ± 2 56.2 ± 0.0 58.7 ± 2.9 
L-NP w/o 147 ± 3 50 ± 5 -,- -,- 
HRP 143 ± 1 45 ± 2 97.6 ± 0.4 94.3 ± 3.4 
EE: encapsulation efficiency; HD: hydrodynamic diameter; HRP: horseradish 
peroxidase; ZP: zeta potential 
A L-NPs S-NPs 
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4.4.2. S-NPs preserved OCT4 activity in vitro more than L-NPs 
Recombinant OCT4 has been shown to become rapidly degraded under cell culture 
conditions (Bosnali et al., 2008). We therefore tested the OCT4 DNA-binding activity 
by electrophoretic mobility shift assays using an oligonucleotide an octamer-binding 
site from the Ig heavy chain enhancer. Soluble OCT4 as well as OCT4 encapsulated 
in S-NPs induced the appearance of specific DNA/protein complex, which was not 
detectable with the negative control BSA (Figure 4.15 A) or in the presence of 50-fold 
excess of unlabeled oligonucleotide (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: S-NPs preserved the activity of OCT4 protein under different 
conditions 
 
(A) EMSA analysis showing OCT4 stabilization by S-NPs but not L-NPs. Unloaded S-NPs, 
soluble OCT4 protein as well as OCT4 encapsulated in S-NPs and L-NPs were subjected to 
EMSA analysis. The DNA-binding activity of OCT4 was analyzed using an oligonucleotide 
containing the OCT4 consensus motif. BSA was used as a negative control. (B-D) OCT4-
loaded S-NPs stabilize OCT4 DNA-binding activity for 7 weeks at 4°C (B), for 14 days at RT 
(C), and for 24 h under cell culture conditions at 37°C in the presence of serum (D), whereas 
the DNA-binding activity of soluble OCT4 is rapidly lost under these conditions. The slowly 
migrating protein/DNA complex of soluble OCT4 shown in (D) is presumably caused by 
aggregation of the OCT4 protein under cell culture conditions. The protein amount used per 
lane for the EMSAs corresponds to 30 ng (A), 100 ng (B) and 250 ng (C, D) 
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In comparison to S-NPs, OCT4-loaded L-NPs induced a much weaker 
electrophoretic shift (Figure 4.15 A). Similar results obtained with higher L-NP 
concentrations (data not shown), indicating a less efficient release of OCT4 from L-
NPs. Further experiments were therefore only conducted with OCT4-loaded S-NPs.  
 
We next tested several storage conditions of the NPs for OCT4 DNA-binding. 
Whereas the long-term storage of OCT4-loaded NPs still retained DNA-binding 
activity even after 7 weeks, no DNA-binding activity could be retained with soluble 
OCT4 protein (Figure 4.15 B). Furthermore, at RT DNA binding of soluble OCT4 was 
lost within 7 days, whereas OCT4-loaded S-NPs showed still DNA binding after 14 
days (Figure 4.15 C). Importantly, S-NPs were able to maintain OCT4 DNA-binding 
activity even in cell culture conditions at 37°C (Figure 4.15 D). In contrast, at 37°C 
soluble OCT4 caused the appearance of high molecular weight complex with 
reduced mobility (Figure 4.15 D), which was presumably due to the reported 
precipitation and aggregation of OCT4 under the cell culture condition in the 
presence of serum (Bosnali and Edenhofer, 2008; Thier et al., 2010). Thus, 
encapsulation of OCT4 in S-NPs results in a considerable stabilization of OCT4 
DNA-binding activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: S-NPs provided a sustained release profile in vitro 
 
Kinetics of HRP release from S-NPs and L-NPs in comparison to free HRP, as measured by 
enzyme activity. Results are given as mean ± SD from three experiments performed in 
triplicate. Similar release profiles were obtained by measuring protein content. 
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4.4.3. S-NPs provided a sustained release profile of HRP model 
protein 
To demonstrate that chitosan NPs preserve protein activity we initially encapsulated 
horseradish peroxidase (HRP) as a model protein and investigated the encapsulation 
efficiency and release profile from small (S-NPs) and large (L-NPs) nanoparticles. 
Moreover, NPs of both sizes were able to release active HRP (Figure 4.16). S-NP 
showed an initial burst during the first 2 h when #12% of the loaded HRP activity was 
released. HRP release slowed down after that reaching #35% release in 72 h. The 
release of HRP from L-NPs was considerably weaker, and only #3.5% of the loaded 
HRP was released after 72 h. 
 
4.4.4. NPs tagging with nuclear localization sequence (NLS) 
enhanced cell surface adsorption and uptake but reduced 
nuclear delivery 
We next investigated whether tagging with an NLS could alter the cellular uptake and 
nuclear delivery of S-NPs. To this end, S-NPs with different NLS densities were 
generated and administered at different concentrations to human fibroblasts. 
Subsequent labeling of the NPs with WGA-FITC in permeabilized and non-
permeabilized cells at different temperatures allowed the discrimination of cell-
associated and internalized NPs. We found that increasing NP concentrations 
resulted in an increased cell association of the NP (Figure 4.17 A) as well an 
increased cell surface binding (Figure 4.17 B) and cellular uptake (Figure 4.17 C). 
Interestingly, the presence of an NLS dose-dependently increased the amount of cell 
surface-bound and internalized S-NPs. FRET spectroscopy with nuclear DNA dye 
Hoechst and FITC was then performed to quantify the nuclear delivery of S-NPs in 
human fibroblasts. Surprisingly and in contrast to the previous experiments, 
unmodified S-NPs revealed a higher FRET efficiency and hence an increased 
nuclear localization compared to NLS-modified NPs (Figure 4.17 D). Thus, even 
though NLS-tagging of S-NPs increased their cellular uptake, nuclear delivery was 
impaired. Since OCT4 exerts its cellular function in the nucleus, further tests were 
conducted with unmodified S-NPs, revealing the highest nuclear delivery. 
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Figure 4.17: NLS density modulated association, surface adsorption, uptake 
and nuclear localization of S-NPs  
 
(A-C) Non-modified S-NPs or S-NPs tagged with low (L), intermediate (I) or high (H) NLS 
densities were incubated at the indicated concentrations with human fibroblasts. After 24 h, 
chitosan NPs were stained as detailed in Material and Methods. The recovered amount of (A) 
cell-associated (i.e. surface-bound and internalized) NPs, (B) NPs bound to cell surface or 
(C) NPs taken up intracellularly was calculated from a standard curve by fluorometry. (D) 
Effects of NLS density on S-NP nuclear delivery as assessed by FRET fluoroscopy. Human 
fibroblasts were treated for 24 h with 250 %g/mL of the indicated versions of S-NPs. 
Measurement of FRET efficiency indicates the strongest colocalization of the nuclear DNA 
dye with SN-Ps lacking an NLS. Results are given as means ± SD. 
 
 
4.4.5. S-NPs delivered OCT4 to the nucleus of hFFn 
We next investigated the cellular distribution of OCT4-loaded S-NPs by confocal 
laser scanning microscopy. To this end, human fibroblasts were treated with equal 
protein amounts of either soluble OCT4 or OCT4-loaded S-NPs. Soluble OCT4 was 
exclusively found at the cell membrane but unable to enter the cells (Figure 4.18 A). 
In contrast, OCT4 encapsulated in NPs was efficiently imported into the fibroblasts, 
as revealed by co-staining for OCT4 using an OCT4 antibody and for chitosan using 
WGA-Alexafluor 488 (Figure 4.18 D-E).  
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Figure 4.18: OCT4-loaded S-NPs but not soluble OCT4 protein were imported 
into cells and partially localized in the cell nucleus 
 
Human primary fibroblasts were treated with 50 %g of each recombinant soluble OCT4 (A-C) 
or OCT4 encapsulated in S-NPs (D-F). After 24 h, cells were stained with OCT4 antibodies 
(green) or for chitosan NPs using WGA-Alexafluor 488 (red). Nuclear DNA was stained with 
Hoechst 33258 (blue). Merged images demonstrate that exogenous soluble OCT4 is 
excluded from cells and adheres to the cell membrane. In contrast, OCT4-loaded S-NPs are 
localized intracellularly, showing a partial overlap with Hoechst nuclear staining. 
 
 
Moreover, this intracellular distribution partially overlapped with nuclear Hoechst 
staining, indicating a potential nuclear delivery of OCT4 (Figure 4.18 F). To further 
analyze a nuclear delivery of the OCT4-loaded NPs in different layers of cell nucleus, 
confocal Z-stack images were collected at 1-µm steps (Figure 4.19). Visualization of 
a Z-stack indeed indicated that OCT4 encapsulated in NPs was detectable in both 
perinuclear and intranuclear regions of the fibroblasts. 
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Figure 4.19: S-NPs delivered OCT4 protein to the nucleus 
 
Z-stack imaging series of human fibroblasts treated with OCT4-loaded S-NPs. Cells were 
treated for 24 h with 50 %g of the SN-Ps and then stained with OCT4-antibody (green), WGA-
Alexafluor 488 (red) and Hoechst 33258 (blue). Z-stack images through cell nucleus were 
collected at 1-%m steps by confocal laser scanning microscopy. The yellow fluorescence of 
the merged imaging indicates the colocalization of OCT4 and S-NPs in perinuclear and 
nuclear regions. The depth in micrometers at which images were taken is indicated. 
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5. Discussion 
5.1. Novel AKT phosphorylation sites 
The self-renewal of pluripotent stem cells is dependent on a coordinated network of a 
key set of transcription factors, which require a tight regulation of their expression to 
maintain pluripotency. OSKM factors have not only attracted increased interest for 
their role in stemness and embryonic pluripotency pathways but also have been 
implicated in tumorigenesis. So far, the mechanisms that regulate the levels of 
OSKM factors are poorly understood and only partially controlled by transcriptional 
events. For instance, SOX2 and OCT4 promote their own transcription by 
cooperative binding to adjacent DNA sites in the promoter regions of their genes 
(Chew et al., 2005). Recent evidence highlights an important role of post-translational 
modifications in regulating the levels and activity of pluripotency factors (Cai et al., 
2012). However, although the transcriptional targets of these factors have been 
extensively studied, very little is known about how the proteins are regulated at the 
post-translational level.  
 
The main intention or the present work was to establish an efficient in vitro system to 
study post-translational modifications of the OSKM factors. To this end, we employed 
a baculovirus expression system for GST fusion proteins in Sf9 insect cells. We 
demonstrate that, with the exception of c-MYC, all OSKM factors were localized in 
the nuclear compartment and could be therefore efficiently enriched from nuclear 
fractions of Sf9 cells. In contrast to our study, previous in vitro phosphorylation 
studies used recombinant transcription factors expressed in bacteria (Brumbaugh et 
al., 2012; Lin et al., 2012b). Bacterial expression systems exhibit several limitations 
because the recombinant proteins are mostly localized in inclusion bodies, requiring 
protein denaturation and an often inefficient refolding (Singh and Panda, 2005). In 
line with this notion, we found that several commercial preparations of bacterially 
expressed OSKM factors lacked robust DNA-binding activity. In contrast, consistent 
with their function as transcription factors, the baculovirally expressed OSKM factors 
revealed strong DNA-binding activity to their consensus sequences.  
 
We chose to study AKT-mediated phosphorylation of the OSKM factors, because, in 
addition to its established function as a survival factor, AKT is regarded as an 
important regulator of stemness (Lin et al., 2012b; Watanabe et al., 2006). It is 
involved in many important cellular activities like cell-cycle progression and 
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metabolism (Figure 5.1). Moreover, increasing evidence indicates that AKT exerts an 
essential function in cancer stem cell biology (Martini et al., 2014; Merz et al., 2015). 
By combining in vitro phosphorylation and phosphoproteomic analyses, we were able 
to identify several novel putative AKT phosphorylation sites in the OSKM factors with 
the exception of c-MYC. For OCT4 we confirmed not only the previously reported 
AKT phosphorylation site T235 (Brumbaugh et al., 2012; Lin et al., 2012b), but also 
found new phosphorylation sites at S136, T159, T225 and S236. Likewise, for KLF4, 
we identified the reported AKT target site at S429 (Chen et al., 2013) as well as 
novel phosphorylation sites at S19, T33, S234 and S326. Despite several attempts, 
however, we were unable to verify the reported T116 site (equivalent to T118 in 
mouse) on SOX2 (Jeong et al., 2010), but identified a novel SOX2 phosphorylation 
site at S83. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.1: AKT-mediated cellular processes 
 
AKT has an essential role in many cellular activities in the cytoplasm as well as in the nucleus. 
It mediates cell-cycle progression and inhibition of differentiation. The newly discovered AKT-
mediated phosphorylation sites in OCT4, SOX2 and KLF4 can have significant effects on 
their nuclear localization and transcriptional activity, which certainly will affect the pluripotency 
and differentiation potential of stem cells. 
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It was reported that AKT-mediated phosphorylation of OCT4 at T235 promotes self-
renewal, survival and the tumorigenic potential of embryonal carcinoma cells (Lin et 
al., 2012b). Mechanistically, AKT-mediated phosphorylation prevents its nuclear 
export and subsequent cytosolic degradation, resulting in increased stability and 
transcriptional activity of OCT4. Similarly, phosphorylation of OCT4 at the adjacent 
S236 site is likely to influence OCT4 activity (Saxe et al., 2009). Interestingly, the 
newly discovered site T225 in OCT4 is localized in POU DNA-binding domain, 
suggesting that phosphorylation at T225 might influence the DNA-binding and 
transcriptional activity of OCT4. Similar to OCT4, also the novel phosphorylation site 
of SOX2 at S83 is located within the DNA-binding domain as well as in one of the 
two nuclear localization sequences of SOX2. This might hint at the possibility that 
AKT-mediated phosphorylation of SOX2 might influence its nuclear import and DNA-
binding activity. It should be noted that SOX2 can be also phosphorylated at T118 by 
AKT which not only promotes SOX2 stability in mouse embryonic stem cells, but its 
activity to reprogram mouse embryonic fibroblasts (Jeong et al., 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Post-translational regulatory studies that can be done using the 
recombinant OSKM 
 
Recombinant transcription factors OSKM presented in this study can be used for further post-
translational regulatory studies. 
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How the AKT-mediated phosphorylation of KLF4 affects nuclear localization or 
transcriptional activity remains unknown. Interestingly, both the reported 
phosphorylation site at T429, which is equivalent to mouse T399 (Chen et al., 2013), 
as well as the newly identified T33 site are located in one of the two nuclear 
localization sequences of KLF4.  
 
All phosphorylation sites that we identified in OCT4, SOX2 and KLF4 are also 
present in the mouse proteins with one exception: S326 in human KLF4 is not 
present in mouse Klf4. The novel sites discovered in this study are therefore valuable 
candidates for in vivo validation and further functional analyses. Recent evidence 
demonstrates that, in addition to phosphorylation events, further post-translational 
modifications, including ubiquitination, sumoylation, methylation, acetylation or O-
GlcNAcylation, may regulate the levels and activity of pluripotency factors (Cai et al., 
2012). Our in vitro system will be also useful to study these post-translational 
modifications as well as their potential crosstalk in the OSKM factors (Figure 5.2).  
 
5.2. Chitosan nanoparticles for efficient nuclear 
delivery of proteins 
Since the introduction of the iPSC technology various strategies have been 
suggested to accomplish transgene-free derivation of iPSCs, including the use of 
non-integrating viruses, site-specific recombinases for transgene excision after 
reprogramming, plasmids or RNA transfection (Kaji et al., 2009; Okita et al., 2010; 
Sommer et al., 2010; Stadtfeld et al., 2008; VandenDriessche et al., 2009; Warren et 
al., 2010; Yu et al., 2009). Although these methods significantly reduce the risk of 
genome alterations, a nucleic acid-free system is generally preferred. Chitosan NPs 
are increasingly used as efficient protein delivery vehicles due to their mild 
formulation conditions in aqueous solvents. Several in vitro and in vivo tests have 
been performed with active proteins encapsulated in chitosan NPs (Agnihotri et al., 
2004; Enríquez de Salamanca et al., 2006; Pan et al., 2002; Vila et al., 2004). To 
demonstrate that chitosan NPs preserve protein activity we initially encapsulated 
HRP as a model protein and investigated the encapsulation efficiency and release 
profile from S-NPs and L-NPs. Both S-NPs and L-NPs were able to release HRP 
activity in its active form. Since S-NPs, however, revealed a more efficient release 
and better preservation of OCT4 DNA-binding activity, further experiments were 
solely conducted with S-NPs.  
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Figure 5.3: Barriers to nuclear delivery and mechanisms of NP nuclear 
delivery 
 
Cell membrane, endosomal entrapment and nuclear membrane present the major barriers to 
NP nuclear delivery. However, chitosan NPs circumvent these hindrances via different 
mechanisms. The figure was adapted and modified from Tammam et al., 2016b. 
 
An ideal protein transduction method has to fulfill a number of criteria and (1) 
stabilize the recombinant protein, (2) facilitate cellular entry and endosomal escape, 
(3) allow cell treatment with sufficient protein concentrations and (4) provide 
sustained protein levels that are required for iPSCs reprogramming without the need 
for repeated treatments. Compared to L-NPs, S-NPs showed a higher sustained 
release of active HRP over a 72-h incubation period and were able to increase OCT4 
stability at 4°C (up to 7 weeks), at room temperature (up to two weeks) and more 
importantly in cell culture at 37°C. Under cell culture conditions the DNA-binding 
activity of OCT4 protein was lost within 1 h, whereas NP-encapsulated OCT4 
preserved activity throughout the 24-h period tested. Also Bonsali et al. reported that 
a rapid loss of TAT-OCT4 activity under cell culture conditions (Bosnali and 
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Edenhofer, 2008). The presence of serum could stabilize both TAT fusion proteins 
but at the same time reduced their cellular uptake (Thier et al., 2010). Protein 
concentration was also reported to be limiting factor when working with non-purified 
HEK cell lysates containing recombinant OSKM factors (Kim et al., 2009a). Lastly, 
while a combination of serum and serum replacement containing lipid-rich BSA 
improved the stability and cellular uptake of TAT-OCT4, serum replacement was 
cytotoxic to fibroblasts that are mostly used in reprogramming experiments (Thier et 
al., 2010, 2012). 
 
There are many barriers that NPs have to cross to reach the cell nucleus (Figure 5.3). 
It has been repeatedly reported that chitosan NPs can associate with cells (Enríquez 
de Salamanca et al., 2006; Huang et al., 2002). S-NPs can cross the cell membrane 
passively or via caveoli mediated endocytosis circumventing the endosomal/ 
lysosomal destruction pathway (Tammam et al., 2015a). Moreover, due to their 
positively charged surface (#35 mV), S-NPs can escape the endosomal entrapment 
via the proton-sponge effect (Richard et al., 2013). Nuclear entry is achieved either 
by passive entry due to the small NP size (25 nm) or by interaction of the NLS with 
the nuclear pore complex (Fagotto et al., 1998). 
 
Only a few studies differentiated between cell surface-bound and internalized NPs 
(Braun et al., 2014; Cho et al., 2009; Gottstein et al., 2013). Since soluble OCT4 is 
incapable of cell entry, we validated that chitosan NPs are capable of cellular entry 
rather than adhering to the cell surface. To this end, we employed a method that 
exploits the preferential affinity of WGA to chitosan and thereby allows the 
quantification of cell surface-bound and internalized chitosan NPs. In non-
permeabilized cells at 4°C WGA-FITC was not internalized in cells and labeled only 
extracellular chitosan NPs, whereas in permeabilized cells at RT WGA-FITC labeled 
both surface-bound and internalized NPs, making it possible to quantify NPs that had 
been internalized and those that were only adsorbed on the surface (Tammam et al., 
2015b). 
 
For its function as a transcription factor, OCT4 requires its delivery into the nucleus. 
Employing a FRET-based assay to evaluate the nuclear targeting of NPs in intact 
fibroblasts, we surprisingly found that the presence of an NLS even reduced nuclear 
targeting of OCT4. Further experiments were therefore conducted with unmodified 
NPs. Confocal microscopy confirmed the cellular and nuclear entry of intact OCT4-
NPs. Prior to microscopy, we treated the permeabilized cells with WGA-Alexafluor 
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488 to demonstrate that the green fluorescence seen was due to OCT4-NPs rather 
than free OCT4. Since WGA preferentially binds to chitosan NPs (Tammam et al., 
2015b), the detectable yellow fluorescence indicated a co-localization of OCT4 and 
WGA, which further implied that the signal was due to intracellular OCT4-NPs rather 
than to soluble OCT4. 
 
Apart from stabilizing OCT4 and delivering it to its site of action, NPs enable the use 
of high concentrations of reprogramming factors. In the case of OCT4, an 
encapsulation efficiency of #75% was achieved, which allowed cell treatment with a 
concentration of 100 %g/mL (#2.6 %M) of OCT4. At this concentration (corresponding 
to 1 mg/mL chitosan) OCT4 was neither degraded, precipitated nor were the target 
cells affected. In line, we have previously demonstrated that S-NPs do not affect cell 
viability up to concentrations of 1 mg/mL (Tammam et al., 2015b). 
 
So far, only two recent studies attempted to employ nanocarriers in protein-induced 
reprogramming. Cho et al. used TiO2 nanotubes with electrostatically adsorbed Oct4, 
Sox2, Klf4 and Nanog for reprogramming of neural stem cells (Cho et al., 2013). 
While the authors observed stem cell-like morphological changes, fully 
reprogrammed iPSCs were not obtained. It is possible that the electrostatic binding, 
unlike chitosan encapsulation of proteins used in our study, hindered the release of 
the reprogramming factors. It is noteworthy that TiO2 nanotubes are not 
biodegradable, and therefore additional studies are required to exclude their long-
term toxicity.  
 
Khan et al. successfully obtained iPSCs colonies from human fibroblasts using 
synthetic surfactants, known as bolaamphiphiles, which were complexed with KLF4, 
SOX2 and NR5A2 (Khan et al., 2013). The authors demonstrated that fully 
reprogrammed iPSCs could be obtained following three rounds of protein 
transduction. In addition, there are several other possibilities to enhance the 
efficiency of iPSC generation.  
For instance, it was recently demonstrated that activation of toll-like receptor-3 
enhances the reprogramming efficiency of cell-permeant OSKM fusion proteins, 
presumably by facilitating epigenetic alterations (Lee et al., 2012b). Similarly, histone 
deacetylase inhibitors, such as valproic acid, have been shown to improve protein-
based iPSC generation (Zhou et al., 2009). 
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Low efficiencies could generally be attributed to the poor stability and solubility of 
recombinant factors, their low cellular entry or their poor endosomal release (Bosnali 
and Edenhofer, 2008; Kim et al., 2009b; Thier et al., 2010). Indeed, a major 
drawback of PTD fusion proteins is that their release from endosomal vesicles into 
the cytosol is inefficient. Interestingly, cell permeabilization with streptolysin O has 
been reported to enhance protein-induced reprogramming, presumably by avoiding 
entrapment and degradation of the OSKM factors in lysosomes (Cho et al., 2010). 
Similarly, sucrose, which also acts as a lysomotrophic agent, can increase the 
reprogramming efficiency of OCT4-TAT (Thier et al., 2010). 
 
Although cell-permeant PTD-fused OKSM factors enhance the cellular uptake, they 
do not provide a sustained supply of the pluripotency factors, unless protein 
treatment is repeated several times. A sustained supply of the OSKM factor is 
required for reprogramming and a major reason for the high reprogramming 
efficiency of retroviral expression systems. In this context, NP-encapsulated OSKM 
factors might provide a more sustained supply compared to soluble proteins. Further 
studies are therefore ongoing to generate NPs for SOX2, c-MYC and KLF4 and to 
evaluate their utility in protein-based iPSC generation. 
 
In conclusion, protein transduction techniques are still poorly developed and highly 
inefficient for the protein-based generation of iPSCs with recombinant 
reprogramming factors. Although protein-based techniques are regarded as safe and, 
unlike retroviral approaches, devoid of potential mutagenic side effects, the limited 
solubility, weak stability under cell culture conditions, the low cellular entry as well as 
the poor endosomal release of the recombinant factors together with a lack of their 
sustained expression are major bottlenecks for successful reprogramming 
approaches. Therefore, further developments of protein delivery systems are 
required to enhance the efficiency of cellular reprogramming to iPSCs. 
 
In the present study we developed a NP-based delivery system for the transcription 
factor OCT4 as the most important reprogramming factor. Following its baculoviral 
expression, recombinant OCT4 was encapsuled in chitosan NPs. Our results 
demonstrate that, compared to soluble OCT4, NP encapsulation of OCT4 stabilized 
its activity and resulted in increased DNA binding as well as in its efficient cellular 
delivery into human fibroblasts. Our study therefore demonstrates a proof-of-concept 
for a DNA-free protein transduction system and suggests that chitosan NPs provide 
are promising tools for the generation of transgene-free iPSCs. 
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5.3. Aurora Kinase A: Kinase function not needed? 
Aurka is of absolute importance for normal embryonic development. Aurka knockout 
mice die early before reaching the 16-cell stage due to mitotic defects, in particular, 
due to defects in spindle assembly (Lu et al., 2008). However, there is growing 
evidence that Aurka immense importance is not only due to its kinase function (Kress 
and Gotta, 2011). Intriguingly, Toya et al. showed that the kinase function of the 
Aurora kinase A homologue (AIR-1) in C. elegans is dispensable in microtubule 
spindle assembly (Toya et al., 2011).  
 
Aurka has been described as a major regulator of self-renewal and pluripotency in 
mESCs. Upon its knockdown, Oct4 was downregulated and cells started 
differentiation in the ectodermal and mesodermal lineages. This has been mainly 
attributed to Aurka-p53 interaction (Lee et al., 2012a).  
 
Our results confirmed the importance of Aurka in pluripotency maintenance, however, 
due to another mechanism of action. AURKA overexpression led to enhanced OCT4 
and c-MYC transcriptional activity of the Ig %E4 luciferase reporter, where the E-box 
and octamer-binding motif were nearby. Interestingly, this effect was kinase-
independent, because, upon the overexpression of the kinase-dead mutant  (AURKA 
KD), the same enhancement was observed. However, AURKA’s effect on c-MYC 
and OCT4 transcriptional activity could not be observed in two further reporters 
(Appendix figure 11.1 and 11.2) where either the E-box or octamer binding-motif was 
present but not both, indicating that the interaction depends on the presence of the 
three proteins and their binding sites. Notably, AURKA overexpression in mESC 
stabilized c-Myc protein as well as the KD mutant. However, knockdown of Aurka 
reduced Oct4 protein, which has been described to be a major trigger for mESC 
differentiation (Wagner and Cooney, 2009) 
 
Lee et al. observed that Aurka inhibition with its specific inhibitor MLN8237 or its 
knockdown reduced reprogramming efficiency of MEFs to iPSCs due to increased 
p53 activity. We confirmed this observation. Nevertheless, we attribute the reduced 
reprogramming efficiency mainly due to reduced c-Myc and Oct4 activation on the 
transcriptional level. These results are opposing to the report published by Li and 
Rana (2012). They defined Aurka as a barrier kinase to reprogramming and showed 
that upon Aurka inhibition with MLN8237 or Aurka depletion with siRNA, the 
reprogramming efficiency was diminished (Li and Rana, 2012). 
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MLN8237 is a potent and selective AURKA inhibitor, which is currently in phase II 
clinical trials as a treatment for many solid tumors (Cheung et al., 2009; Manfredi et 
al., 2011). MLN8237 has been described to have diverse effects on AURKA and its 
interaction partners in stem cells. In one report, MLN8237 inhibited Aurka but, as a 
feedback, it increased its protein expression in a concentration dependent manner. 
Moreover, MLN8237 did not affect the pluripotency and self-renewal potential of 
mESCs (Li and Rana, 2012). However, in another report, MLN8237 completely 
abrogates the self-renewal potential of mESCs and initiates differentiation to 
ectodermal and mesodermal lineages (Lee et al., 2012a). 
 
Due to the discrepancy of the published reports concerning MLN8237, we performed 
an extensive study on the effects of MLN8237 in mESCs. Remarkably, low 
concentrations (1-10 nM) of MLN8237 did not inhibit Aurka, however, it increased its 
protein level and its activity as observed by p-Aurka antibody. This increase in Aurka 
levels was accompanied by an increase in c-Myc protein level. Higher concentrations 
(1-10 %M) of MLN8237 inhibited Aurka and decreased its protein level. This decrease 
was however accompanied with a decrease in c-Myc and Oct4 proteins. 
 
In summary, Aurora kinase A plays a critical role in the regulation of stem cell 
transcription factors c-Myc and Oct4, however, mainly in a kinase-independent 
manner. In our study, overexpression of the active kinase and the kinase-dead 
mutant increased the transcriptional activity of c-Myc and Oct4 in luciferase assays 
and stabilized c-Myc in mESCs. We confirmed that inhibition of Aurka reduced the 
reprogramming efficiency of MEFs to iPSCs. High concentrations of MLN8237 
destabilize Aurka, c-Myc and Oct4 impairing the self-renewal and pluripotency of 
stem cells. Moreover, we shed the light on the effects of MLN8237 in the 
reprogramming process. MLN8237 decreased the mRNA levels of c-Myc and Oct4 
during the reprogramming process diminishing the reprogramming efficiency of 
MEFs to iPSCs. 
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6. Summary 
Stem cells possess intricate regulatory networks governed by the key transcription 
factors OCT4, SOX2, KLF4 and c-MYC (OSKM). OSKM transcriptional activity and 
stability are regulated by different post-translational modifications (PTMs), especially 
by phosphorylation. AKT (also known as Protein Kinase B) is essential for self-
renewal and pluripotency maintenance of stem cells. It phosphorylates OCT4, SOX2 
and KLF4 on several sites. However, the comprehensive phosphorylation pattern 
remains elusive. In the first project of this study, we established an in vitro tool to 
explore PTMs in the transcription factors OSKM, especially, phosphorylation by AKT 
kinase. For this purpose, OSKM were expressed in Sf9 insect cells using the 
Baculovirus Expression Vector System (BEVS). BEVS ensured high yield of properly 
folded proteins harboring PTMs similar to their mammalian counterparts. 
Recombinant OSKM were confirmed for purity, nuclear localization and biological 
activity. Furthermore, by combining in vitro kinase assays with mass spectrometry-
based phosphoproteomic analyses, novel AKT phosphorylation sites were identified 
in OCT4, SOX2 and KLF4 in vitro.  
 
c-MYC and OCT4 have been identified in a previous study in our lab as putative 
phosphorylation substrates to Aurora kinase A (AURKA). AURKA is an essential 
kinase in cell cycle and has various implications in cancer and stem cells. In the 
second project of this study, we investigated the interaction between AURKA, c-MYC 
and OCT4. Remarkably, AURKA increased the transcriptional activity of c-MYC and 
OCT4 in a kinase-independent manner. MLN8237, a specific Aurora kinase A 
inhibitor regulated the transcription and the protein stability of c-Myc and Oct4 in 
mouse embryonic stem cells and during reprogramming of mouse embryonic 
fibroblasts. Taken together, we showed that Aurka stabilized c-Myc and Oct4 and its 
kinase function was not needed in stem cells. 
 
Ectopic overexpression of OSKM has been shown to reprogram terminally 
differentiated cells to become induced pluripotent stem cells. Conventionally, viral 
vectors are used for transduction increasing the risk of genetic manipulations by viral 
integrations in the host genome. Therefore, in the third project of this study, we 
established an integration-free, protein-based reprogramming method using 
biodegradable chitosan nanoparticles (NPs) loaded with recombinant OCT4 protein. 
NPs delivered OCT4 to the nucleus of human dermal fibroblasts and provided a 
sustained release profile to its cargo. Moreover, NPs stabilized OCT4 activity in vitro.  
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7. Zusammenfassung 
 
Stammzellen besitzen komplexe regulatorische Netzwerke, die von den 
Transkriptionsfaktoren OCT4, SOX2, KLF4 und c-MYC (OSKM) gesteuert werden. 
Die transkriptionelle Aktivität und die Stabilität der OSKM Faktoren werden durch 
verschiedene posttranslationale Modifikationen (PTMs) geregelt, insbesondere, 
durch die Phosphorylierung. AKT, auch Protein-Kinase B genannt, ist für die 
Selbsterneuerung und die Erhaltung der Pluripotenz von Stammzellen unentbehrlich. 
Sie phosphoryliert OCT4, SOX2 und KLF4 an mehreren Stellen. Allerdings ist das 
Phosphorylierungsmuster noch unbekannt. Im ersten Projekt dieser Studie haben wir 
ein in vitro Werkzeug entwickelt, um die PTMs in den Transkriptionsfaktoren OSKM, 
vor allem die Phosphorylierung durch die AKT Kinase zu erforschen. Die OSKM 
wurden in Sf9 Insektenzellen mit Hilfe des Baculovirus-Expressionsvektor-Systems 
(BEVS) exprimiert. Der Einsatz von BEVS erlaubte eine hohe Expression von richtig 
gefalteten Proteinen, die ähnliche PTMs wie Säugerzellen besitzen. Die 
rekombinanten OSKM Proteine wurden auf ihre Reinheit, nukleäre Lokalisation und 
biologische Aktivität getestet. Darüber hinaus wurden durch Massenspektrometrie-
basierte Phosphoproteom-Analysen neue AKT-Phosphorylierungsstellen in OCT4, 
SOX2 und KLF4 identifiziert. 
 
C-MYC und OCT4 wurden in unserem Labor als putative Phosphorylierung-
Substrate der Aurora-Kinase A (AURKA) identifiziert. AURKA spielt eine wichtige 
Rolle im Zellzyklus und hat verschiedene Auswirkungen auf Krebs und Stammzellen. 
Im zweiten Projekt dieser Studie untersuchten wir die Interaktion zwischen AURKA, 
c-MYC und OCT4. Interessanterweise erhöhte AURKA die transkriptionelle Aktivität 
von c-MYC und OCT4, in einer Kinase–unabhängigen Regulation. MLN8237, ein 
spezifischer AURKA Inhibitor, regulierte die Transkription und die Proteinstabilität 
von c-MYC und OCT4 in murinen embryonalen Stammzellen, aber auch bei der 
Reprogrammierung von murinen embryonalen Fibroblasten. Zusammengenommen 
haben wir gezeigt, dass Aurka c-Myc und OCT4 stabilisiert und dass ihre 
Kinasefunktion in Stammzellen hierfür nicht benötigt wird. 
 
Es wurde gezeigt dass die ektopische Überexpression von OSKM die 
Reprogrammierung von differenzierten Zellen zu pluripotenten Stammzellen, 
induziert. Üblicherweise werden virale Vektoren zur Transduktion verwendet, was die 
Gefahr von genetischen Manipulationen durch die virale Integration in das 
Zusammenfassung 
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Wirtsgenom, erhöht. Im dritten Projekt dieser Studie haben wir eine integrationsfreie, 
proteinbasierte Reprogrammierungsmethode durch Verwendung von biologisch 
abbaubaren Chitosan-Nanopartikeln (NPs) entwickelt, die mit OCT4 rekombinanten 
Proteinen beladen waren. NPs beförderten OCT4 zum Zellkern von humanen 
dermalen Fibroblasten und erlaubten eine anhaltende Freisetzung von OCT4. 
Darüber hinaus stabilisierten die NPs in vitro die OCT4 Aktivität. 
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11. Appendix 
Two further firefly luciferase reporters were utilized to confirm the kinase-
independent regulation between AURKA on one side and c-MYC and OCT4 on the 
other side. The first reporter: E-box luciferase reporter (Figure 11.1) encodes the 
firefly luciferase gene under the control of a minimal (m) CMV promoter and tandem 
repeats of the c-Myc responsive element (E-box consensus CACGTG). The second 
reporter: Octamer luciferase reporter (Figure 11.2), likewise, encodes for firefly 
luciferase gene under the control of mCMV promoter but with tandem repeats of 
OCT4 responsive element (Octamer motif ATTTGCAT). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.1: AURKA reduces c-MYC transcriptional activity on E-box reporter 
 
Luciferase assay in HEK293 FT cells upon overexpression of c-MYC, OCT4, AURKA or 
AURKA kinase dead mutant (KD) using a firefly reporter coding for E-box binding site 
CACGTG. Cells were transfected with the indicated DNA, E-box firefly luciferase reporter and 
a constitutively expressing renilla construct as a transfection control. Cells were harvested 48 
h after transfection. Luminescence values were normalized on renilla and GFP controls. n=3, 
results are expressed as mean ± sd. * p< 0.05, ** p< 0.01, *** p< 0.001. 
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In E-box reporter, upon overexpression of AURKA, the transcriptional activity of c-
MYC in the luciferase assay decreased. Surprisingly, the same decrease was 
noticed upon overexpression of AURKA KD mutant (Figure 11.1). c-MYC 
overexpression did not increase the signal. This could be attributed to the prevalence 
of c-MYC in HEK293 FT cells. Therefore to confirm the specificity and sensitivity of 
the reporter towards c-MYC, luciferase assay with the same settings was performed 
in MEF cells, which have lower levels of c-MYC. In MEFs, c-MYC overexpression 
increased the relative luciferase activity 2 folds relative to the control (data not 
shown). OCT4 overexpression did not give any signal indicating the specificity of the 
reporter to c-MYC. However, overexpression of OCT4 together with c-MYC resulted 
in increase in the luciferase readout (Figure 11.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.2:  AURKA reduces OCT4 transcriptional activity on octamer motif 
 
Luciferase assay in HEK293 FT cells upon overexpression of c-MYC, OCT4, AURKA or 
AURKA kinase dead mutant (KD) using a firefly reporter coding for octamer motif ATTTGCAT. 
Cells were transfected with the indicated DNA, octamer luciferase reporter and a 
constitutively expressing renilla construct as a transfection control. Cells were harvested 48 h 
after transfection. Luminescence values were normalized on renilla and GFP controls. n=3, 
results are expressed as mean ± sd. * p< 0.05, ** p< 0.01. 
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In Octamer reporter, similar results were observed, upon overexpression of AURKA 
or AURKA KD, the relative luciferase activity dropped in the absence of OCT4 or 
MYC or both. OCT4 overexpression highly activated the transcription of the 
luciferase gene increasing the signal to 200 folds. c-MYC did not have any effect 
indicating the specificity of the reporter to OCT4. However, AURKA or AURKA KD 
overexpression decreased the relative luciferase activity to the half when 
overexpressed with OCT4 or c-MYC or both (Figure 11.2). 
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The four OSKM factors OCT4, SOX2, KLF4 and c-MYC are key transcription factors modulating pluripotency, self-
renewal and tumorigenesis in stem cells. However, although their transcriptional targets have been extensively studied,
little is known about how these factors are regulated at the posttranslational level. In this study, we established an in
vitro system to identify phosphorylation patterns of the OSKM factors by AKT kinase. OCT4, SOX2, KLF4 and c-MYC were
expressed in Sf9 insect cells employing the baculoviral expression system. OCT4, SOX2 and KLF4 were localized in the
nucleus of insect cells, allowing their easy puriﬁcation to near homogeneity upon nuclear fractionation. All transcription
factors were isolated as biologically active DNA-binding proteins. Using in vitro phosphorylation and mass
spectrometry-based phosphoproteome analyses several novel and known AKT phosphorylation sites could be
identiﬁed in OCT4, SOX2 and KLF4.
Introduction
Stem cells require intricate regulatory networks governed by a
limited number of key transcription factors in order to maintain
self-renewal and pluripotency. Essential for these processes are
the so-called OSKM factors including the transcription factors
OCT4, SOX2, KLF4 and c-MYC.1 The ectopic expression of
solely OSKM factors is sufficient to reprogram terminally differ-
entiated cells back to pluripotency in both human and mouse sys-
tems.2,3 OSKM transcription factors are involved not only in
pluripotency and differentiation of stem cells, but also in tumori-
genesis.4-11
The expression of OSKM factors is controlled in a coordi-
nated manner by several feedback loops and requires a tight regu-
lation to maintain stem cell potential. A slight change in the
amount of the proteins can lead to drastic alterations in cell fate
that may eventually result in tumorigenesis. For instance, the
level of OCT4, also known as POU5F1, is crucial for cell fate
transitions and embryonic development.12,13 If OCT4 protein is
elevated more than 2-fold compared to normal conditions, stem
cells loose their pluripotency and start differentiation into endo-
derm and mesoderm.14 Moreover, a moderate increase of OCT4
is sufficient to cause to tumorigenesis e.g. of gonadal tumors.15
Both the expression levels and transcriptional activity of OSKM
factors are fine-tuned by various posttranslational modifications,
such as sumoylation, acetylation, methylation, O-GlcNAcylation
and phosphorylation.16-22 Recent evidence suggests that the serine/
threonine kinase AKT plays a critical role not only in tumorigene-
sis, but is also required for self-renewal and pluripotency of normal
cells.23-25 AKT1 has been shown to directly phosphorylate OCT4,
SOX2 and KLF4, modulating their nuclear localization, stability
and transcriptional activity.26-28 In particular, AKT phosphorylates
OCT4 at T235 leading to enhanced apoptosis resistance and
tumorigenic potential in mouse embryonic carcinoma cells.29 Like-
wise, SOX2 phosphorylation at T118 by AKT results in decreased
proteasomal degradation of SOX2 protein and enhanced self-
renewal capacity of mouse embryonic stem cells.27,30 In contrast,
AKT-mediated phosphorylation of human KLF4 on T429 acceler-
ates its degradation and thereby impairs stemness.31 In addition to
triggering posttranslational modifications, indirect links between
AKT and certain OSKM factors, such SOX2, have been described.
In mice, Akt has been suggested to repress Sox2 transcription via a
regulatory circuit involving FoxO1.28 Moreover, AKT was
reported to regulate SOX2 transcriptional activity via p27 and
miR-30a in nasopharyngeal cancers.32 AKT mediates posttransla-
tional modifications of the OSKM factors but, conversely,
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posttranslational modifications of OCT4 might also modulate
AKT activity, thereby forming a positive feedback loop.26,29 Thus,
these data point to multiple mutual links between AKT and the
OSKM factors, which might be critical for maintenance of stem-
ness in malignant and non-malignant stem cells.
Despite the increasing evidence for the interaction of AKT
with OSKM factors, the AKT-specific phosphorylation sites of
the OSKM factors are still incompletely understood. Previous in
vitro phosphorylation studies have been solely performed with
recombinant OSKM proteins expressed in bacteria.29,33 This
approach exhibits several limitations, because the transcription
factors are mostly expressed in inclusion bodies and need to be
denatured and refolded in vitro. However, refolding of proteins
from inclusion bodies is challenging and usually results in poor
yields of natively folded, bioactive proteins.34
In the present study we developed a reliable in vitro tool to
identify the AKT phosphorylation sites, based on the baculoviral
expression of OCT4, SOX2, KLF4 and c-MYC in insect cells.
This expression system is capable of performing most mamma-
lian post-translational modifications, which are crucial for the
regulation of transcriptions factors.35 We show that all OSKM
factors can be purified in a simple manner to near homogeneity
as native proteins and – similar to their mammalian counterparts
– retain essential activities, such as nuclear translocation and
DNA binding. Using in vitro kinase assays coupled with mass
spectrometry-based phosphoproteomics we could not only con-
firm previously reported phosphorylation sites, but were able to
identify several new AKT phosphorylation sites within OCT4,
SOX2 and KLF4. The described approach will be also suitable to
explore additional posttranslational modifications of OSKM
transcription factors.
Results
Recombinant OSKM factors translocate to the nucleus of
Sf9 insect cells
A major advantage of the Sf9 baculovirus system is that,
unlike bacterial expression systems, proteins can be produced in a
native form retaining the correct subcellular compartmentaliza-
tion and posttranslational modifications. To produce human
OSKM proteins their cDNAs were cloned into the N-terminal
glutathione S-transferase (GST) fusion plasmid pAcG2T. After
cotransfection of the vector with linearized wildtype baculoviral
DNA high-titer virus stocks were produced. To optimize protein
production we first analyzed several multiplicities of infection
(MOI) and incubation periods postinfection. In first fraction-
ation experiments we noticed that OCT4, SOX2 and KLF4 were
predominantly localized in the nucleus of Sf9 cells, whereas c-
MYC was distributed both in cytoplasmic and nuclear fractions,
as revealed by Coomassie staining and Western blotting
(Fig. 1A). For the purification of OCT4, SOX2 and KLF4 we
therefore developed a single-step nuclear extraction protocol,
allowing an easy enrichment of the transcription factors by
nuclear fractionation, whereas c-
MYC was purified from whole cell
lysates.
To prepare nuclear fractions Sf9
cells were swollen in hypotonic
buffer and broken up with a Dounce
homogenizer. Representative micro-
scopic pictures show the successful
nuclear extraction after disruption of
the cell membrane (Fig. 1B). Fol-
lowing lysis of the nuclei for OCT4,
SOX2 and KLF4 or of whole cells
for c-MYC GST-affinity chromatog-
raphy was performed. As revealed by
silver staining, all transcription fac-
tors could be purified to near homo-
geneity (Fig. 1C). Purified KLF4
showed minor protein bands at 50
and 70 kDa, which were recognized
by the KLF4 antibody and, as
revealed by matrix-assisted laser
desorption/ionization (MALDI)
analysis, represented fragments of the
transcription factor (data not shown).
In addition, a minor GST band was
found at 27 kDa, which was most
pronounced for c-MYC, presumably
due to its purification from cell
lysates (Fig. 1C). Importantly, from
Figure 1. Recombinant OCT4, SOX2, and KLF4 are enriched in nuclear fractions of Sf9 insect cells. (A)
Nuclear localization of OSKM factors: Sf9 cells were infected with baculoviruses encoding human OCT4,
SOX2, KLF4 and c-MYC. Two days postinfection for SOX2, KLF4 and c-MYC, and 3 d postinfection for
OCT4 cytosolic and nuclear fractions were prepared and subjected to SDS-PAGE. The upper panel shows
a Coomassie blue staining of the gel with dotted boxes highlighting the protein of interest in the nuclear
fractions. The lower panel shows an immunoblot using a GST antibody for the detection of OCT4, SOX2,
and KLF4 and a MYC antibody for detection of c-MYC. (B) Representative microscopical pictures of the
nuclear extraction. The nucleus (N) of Sf9 cells is shown before and after disruption of the cell membrane.
200x magniﬁcation. (C) SDS-PAGE of the puriﬁed OSKM factors following afﬁnity chromatography on glu-
tathione-coupled sepharose columns. The full-length proteins are marked with a close arrowhead, and
the 27 kD GST fragment of the fusion proteins with an open arrowhead.
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Sf9 suspension cultures considerable protein yields of the tran-
scription factors could be obtained: i.e. OCT4: 6.1 mg/l; SOX2:
1.5 mg/l; c-MYC: 2.8 mg/l and KLF4: 3.8 mg/l.
Recombinant OSKM factors bind to their DNA consensus
motifs in vitro
We next tested the DNA-binding activity of the purified fac-
tors using electrophoretic mobility shift assays (EMSAs) with dif-
ferent DNA consensus motifs (Fig. 2). Even a small amount
(75 ng) of recombinant OCT4 was sufficient to reveal strong
DNA binding to an octamer-binding site from the Ig heavy chain
enhancer (1W motif). A slightly weaker DNA binding of OCT4
was detected to the OCT4-binding site from the enhancer of
undifferentiated embryonic cell transcription factor 1 (UTF1)
which contains an additional adjacent SOX2-binding site
(Fig. 2). In addition, also DNA binding of recombinant SOX2
could be demonstrated to the classical DNA consensus site pres-
ent in the miR-302 promoter as well as to the UTF1 site.36
Moreover, KLF4 bound efficiently to the typical DNA consensus
sequence of the Nanog promoter. DNA binding of recombinant
c-MYC to the classical E-box element was somewhat weaker but
clearly detectable. For all transcription factors DNA-binding was
abolished by competition with unlabeled oligonucleotides (data
not shown). These results therefore suggest that recombinant
OSKM factors retain not only their typical nuclear localization,
but also their DNA-binding activity.
Identification of novel AKT phosphorylation sites in OCT4,
SOX2 and KLF4
In order to investigate AKT phosphorylation sites of the dif-
ferent transcription factors, we incubated all 4 OSKM factors
with active baculovirus-derived recombinant AKT1 in an in-vitro
kinase assay. Subsequent immunoblotting of the reactions mix-
tures with an anti–phospho-(Ser/Thr) AKT substrate antibody,
which recognizes AKT phosphorylation motif sequences,
revealed that OCT4, SOX2 and KLF4 were efficiently phosphor-
ylated by AKT (Fig. 3A). OCT4 showed several degradation
products that were strongly phosphorylated by AKT, whereas no
phosphorylation of c-MYC could be detected.
To identify the AKT phosphorylation sites of the different
transcription factors we subjected in vitro phosphorylated as well
the control OSKM factors to mass spectrometry (MS)-based
phosphoproteomic analysis. As expected, we identified several
intrinsic phosphorylation sites on OCT4 and KLF4 that were
phosphorylated in the absence of ATP and AKT, indicating that
the proteins were modified by the intrinsic phosphorylation
machinery of Sf9 cells. Most phosphorylation sites however were
dependent on AKT and their MS/MS spectra are depicted in
Supplemental Figures 1–9. A representative spectrum of
phosphorylation at of OCT4 at T225 is shown in Figure 3B. As
published previously,29 OCT4 was found to be further phos-
phorylated by AKT at T235. Importantly, our phosphoproteo-
mic analysis identified 4 further unreported sites in OCT4 that
were phosphorylated by AKT, namely, S136, T159, T225 and
S236 (Fig. 4). In addition to OCT4, we found that AKT phos-
phorylated SOX2 at S83, which has been also yet not described.
KLF4 was phosphorylated by AKT at 5 different sites: the already
known residue T429, which is homologous to T399 in mouse,31
and 4 further novel sites, namely, S19, T33, S234 and S326
(Fig. 4, Supplemental Figures 6–9).
Discussion
The self-renewal of pluripotent stem cells is dependent on a
coordinated network of a key set of transcription factors, which
require a tight regulation of their expression to maintain pluripo-
tency. OSKM factors have not only attracted increased interest
for their role in stemness and embryonic pathways, but have
been also implicated in tumorigenesis. So far, the mechanisms
that regulate the levels of OSKM factors are poorly understood
and only partially controlled by transcriptional events. For
instance, SOX2 and OCT4 promote their own transcription by
cooperative binding to adjacent DNA sites in the promoter
Figure 2. Recombinant OSKM factors retain DNA-binding activity. The
puriﬁed OSKM factors were subjected to EMSA analysis. The DNA-bind-
ing activity of OCT4 was analyzed using oligonucleotides containing the
OCT4 1W consensus motif or UTF1 enhancer sequence. SOX2 DNA bind-
ing was analyzed using oligonucleotides containing the SOX2 consensus
motif or the UTF1 enhancer sequence. Similarly, the DNA-binding activity
of KLF4 and c-MYC was tested with oligonucleotides containing the DNA
consensus sequences of the transcription factors. Bovine serum albumin
(BSA) was used as a negative control. The closed arrowheads indicate
the speciﬁc protein-DNA complexes and the open arrowheads the
unbound oligonucleotides.
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regions of their genes.37 Recent evidence highlights an important
role of posttranslational modifications in regulating the levels
and activity of pluripotency factors.38 However, although the
transcriptional targets of these factors have been extensively stud-
ied, very little is known about how the proteins are regulated at
the posttranslational level.
The main intention of the present work was to establish an
efficient in vitro system to study posttranslational modifications
of the OSKM factors. To this end, we employed a baculoviral
expression system for GST fusion proteins. We demonstrate
that, with the exception of c-MYC, all OSKM factors were local-
ized in the nuclear compartment and could be therefore effi-
ciently enriched from nuclear fractions of Sf9 cells. In contrast to
our study, previous in vitro phosphorylation studies used recom-
binant transcription factors expressed in bacteria.29,33 Bacterial
expression systems exhibit several limitations, because the recom-
binant proteins are mostly localized in inclusion bodies, requiring
protein denaturation and an often inefficient refolding.34 In line
with this notion, we found that several commercial preparations
of bacterially expressed OSKM factors lacked robust DNA-bind-
ing activity. In contrast, consistent with their function as tran-
scription factors, the baculovirally expressed OSKM factors
revealed strong DNA-binding activity to their consensus
sequences.
We chose to study AKT-medi-
ated phosphorylation of the OSKM
factors, because, in addition to its
established function as a survival fac-
tor, AKT is regarded as an important
regulator of stemness.25,29 More-
over, increasing evidence indicates
that AKT exerts an essential function
in cancer stem cell biology.39,40 By
combining in vitro phosphorylation
and phosphoproteomic analyses, we
were able to identify several novel
putative AKT phosphorylation sites
in the OSKM factors with the excep-
tion of c-MYC. For OCT4 we con-
firmed not only the previously
reported AKT phosphorylation site
T235,29,33 but also found new phos-
phorylation sites at S136, T159,
T225 and S236. Likewise, for KLF4
we identified the reported AKT tar-
get site at S429 31 as well as novel
phosphorylation sites at S19, T33,
S234 and S326. Despite several
attempts, however, we were unable
to verify the reported T116 site of
SOX2 (equivalent to T118 in the
murine protein),27 but identified a
novel SOX2 phosphorylation site at
S83.
It was reported that AKT-medi-
ated phosphorylation of OCT4 at T235 promotes self-renewal,
survival and the tumorigenic potential of embryonal carcinoma
cells.29 Mechanistically, AKT-mediated phosphorylation pre-
vents its nuclear export and subsequent cytosolic degradation,
resulting in increased stability and transcriptional activity of
OCT4. Similarly, phosphorylation of OCT4 at the adjacent
S236 site is likely to influence OCT4 activity.41 Interestingly, the
newly discovered site T225 in OCT4 is localized in POU DNA-
binding domain, suggesting that phosphorylation at T225 might
influence the DNA-binding and transcriptional activity of
OCT4. Similar to OCT4, also the novel phosphorylation site of
SOX2 at S83 is located within the DNA-binding domain as well
as in one of the 2 nuclear localization sequences of SOX2. This
might hint at the possibility that AKT-mediated phosphorylation
of SOX2 might influence its nuclear import and DNA-binding
activity. It should be noted that murine Sox2 can be also phos-
phorylated at T118 by AKT which not only promotes its stabil-
ity, but also its activity to reprogram mouse embryonic
fibroblasts.27 How the AKT-mediated phosphorylation of KLF4
affects nuclear localization or transcriptional activity remains
unknown. Interestingly, both the reported phosphorylation site
at T429, which is equivalent to mouse T399,31 as well as the
newly identified T33 site are located in one of the 2 nuclear local-
ization sequences of KLF4.
Figure 3. OCT4, SOX2 and KLF4, but not c-MYC are phosphorylated by AKT in vitro. (A) In vitro kinase assay:
The puriﬁed OSKM factors were incubated with active AKT1 protein in the absence or presence of ATP,
and immunoblotted with the indicated antibodies. (B) Representative mass spectrum demonstrating AKT-
mediated phosphorylation of OCT4 at T225 following digestion with LysC.
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With the exception of S326 in human KLF4, all phosphoryla-
tion sites that we identified in OCT4, SOX2 and KLF4 are also
present in the mouse proteins. The novel sites discovered in this
study are therefore valuable candidates for in vivo validation and
further functional analyses. Recent evidence demonstrates that,
in addition to phosphorylation events, further posttranslational
modifications, including ubiquitination, sumoylation, methyla-
tion, acetylation or O-GlcNAcylation, may regulate the levels
and activity of pluripotency factors.38 Our in vitro system will be
also useful to study these posttranslational modifications as well
as their potential crosstalk in the OSKM factors. All constructs
used in this study will be therefore made available to the scientific
community.
Material and Methods
Recombinant protein expression in Sf9 cells
The cDNAs of human OCT4, SOX2, KLF4 and c-MYC
were amplified using Pfx polymerase (Life Technologies) and
flanked with a flag tag and BamH1 site from the 50 end and
EcoR1 site from the 30 end. After digestion with EcoR1 and
BamH1 (Thermo Scientific) and ligation with T4 ligase, the
DNA amplicons were cloned into the insect cell transfer vector
pAcG2T (BD Biosciences) encoding N-terminal GST fusion
proteins. Following transformation of competent NEB 5-a E.
coli the correct cloning of the inserts was verified by restriction
analysis using PvuII. Sf9 insect cells were cultured at 27!C in Ex-
cell 420 medium (Sigma-Aldrich) supplemented with 10% fetal
calf serum (PAA Laboratories). Recombinant baculoviruses were
generated through homologous recombination after calcium
phosphate transfection of the recombinant pAcG2T transfer
vector and Baculogold Bright Linearized DNA (BD Biosciences).
After virus amplification and production of high-titer virus stocks
protein production of the transcription factors was performed in
Sf9 cell suspension cultures. Different multiplicities of infections
(MOIs) and incubation times postinfection were explored for
each transcription factor to optimize protein production.
Purification of recombinant OSKM factors
Sf9 cells were harvested 2 d postinfection for SOX2, KLF4
and c-MYC, and 3 d postinfection for OCT4 at 2500 g for
10 min. OCT4, SOX2 and KLF4 were isolated from purified
Sf9 cell nuclei. To this end, the cell pellet was washed with
PBS and resuspended in a hypotonic buffer containing
10 mM Na-HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM dithiothreitol and 0.5 mM PMSF.
After incubation on ice for 15 min, cells were homogenized
with 25 strokes in a Dounce homogenizer. After centrifugation
at 7000 g for 10 min at 4!C, the nuclear pellet was resus-
pended in 5 pellet volumes of extraction buffer (20 mM Na-
HEPES, pH 7.9, 400 mM KCl, 1 mM EDTA, 1 mM EGTA,
10% glycerol, 1 mM dithiothreitol, 10 nM aprotinin, 10 mM
leupeptin, 0.5 mg/ml pepstatin and 0.5 mM PMSF), and
incubated for 30 min at 4!C with rotation. For c-MYC, whole
cell extraction was performed by incubating the cells for
45 min in ice-cold RIPA lysis buffer (25 mM Tris-HCl, pH
7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate,
0.1% SDS) containing protease inhibitors. Both the nuclear
and whole cell lysates were centrifuged at 50,000 g for 15 min
at 4!C to remove cellular debris and filtered through a
0.45 mm filter. Protein purification was performed using
GSTrap FF 1-ml columns (GE Healthcare) coupled to a peri-
staltic pump. The column was equilibrated with 5 column vol-
umes (CV) of PBS, before the lysates were loaded with a flow-
rate of 1 ml/min. After sample application, the column was
washed with 10 CV PBS and proteins were eluted in 0.5 ml
fractions with 5 CV glutathione elution buffer (10 mM GSH,
50 mM Tris-HCl, pH 8.0) at a flow rate of 0.2 ml/min. All
steps were performed at 4!C.
Coomassie/silver staining and immunoblotting
The recombinant proteins were separated by 10% SDS-
PAGE. For Coomassie staining, gels were stained for 1 h in
staining solution (0.1% Coomassie brilliant blue R-250, 50%
methanol and 10% acetic acid) and destained overnight in 10%
acetic acid, 10% isopropanol and 10% methanol. For silver stain-
ing, gels were fixed for 30 min in 10% acetic acid and 40% etha-
nol, sensitized for 30 min in 40% ethanol, 8 mM Na2S2O3 x 5
H2O, 500 mM sodium acetate, and washed thrice for 5 min in
H2O. After staining in 30 mM silver nitrate solution for 30 min
gels were washed in H2O and developed in 100 ml of a solution
containing 235 mM Na2CO3, 50 ml 37% formaldehyde and
25 ml 10% Na2S2O3 x 5 H2O. For Western blot analysis pro-
teins were transferred onto polyvinylidenedifluoride membranes
(Amersham Biosciences).42,43 Membranes were blocked in PBS
containing 4% BSA and 0.05% Tween-20 for 1 h, followed
by an overnight incubation with the primary antibodies in
Figure 4. AKT phosphorylation sites in OCT4, SOX2 and KLF4. The
scheme shows the novel and previously reported AKT phosphorylation
sites with the functional domains of OCT4, SOX2 and KLF4. OCT4 con-
tains POU-speciﬁc and homeodomain (HD) DNA-binding domains as
well as transactivation domains located at the N-terminus (N-TAD) and
C-terminus (C-TAD). SOX2 has a high mobility group (HMG) DNA-binding
domain and a transactivation domain (TAD). KLF4 contains a single N-ter-
minal TAD, a central proline-rich region (PR) and 3 zinc-ﬁnger (ZF) DNA-
binding domains. NLS marks the nuclear localization sequences of the
transcription factors.
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blocking buffer at 4!C. The following antibodies were used:
mouse anti-GST (Santa Cruz, clone 1E5, 1:1000), mouse anti-c-
MYC (Santa Cruz, clone A-14, 1:1000) and rabbit anti-phos-
pho-(Ser/Thr) AKT substrate (RxRxxS/T) antibody (Cell Signal-
ing, 1:1000). After washing the membrane in TBS/0.05%
Tween and incubation with peroxidase-coupled secondary anti-
bodies for 1 h proteins were visualized using ECL reagents
(Amersham Biosciences).
Electrophoretic mobility shift assay (EMSA)
EMSA was performed using Odyssey! Infrared EMSA Kit
(LI-COR Bioscience) according to the manufacturer’s instruc-
tions. Briefly, the recombinant proteins were incubated with
1 ml of IRDye! 700 infrared dye-labeled double-stranded oli-
gonucleotides, 2 ml of 10 £ binding buffer, 2.5 mM DTT,
0.25% Tween-20 and 1 mg of poly(dI-dC) in a total volume of
20 ml for 20 min at room temperature in the dark. Samples
were separated on 4% native polyacrylamide gels in 0.5 £ Tris-
borate-EDTA buffer. The gel was scanned by direct infrared
fluorescence detection on the Odyssey! imaging system. The
following oligonucleotides with high-affinity binding sites for
the transcription factors were labeled from both 50 and 30 ends
with IRDye 700: OCT4 (GCCGAATTTGCATATTTG-
CATGGCTG), UTF1 (CTGAAAGATGAGAGCCCTCAT
TGTTATGCTAGTGAAGTGCCAAGCTGA), SOX2 (CAGA
TAGAAACACAATGCCTTTCTCGGC), KLF4 (GTAGGG
GGTGTGCCCGCCAGGAGGGGTGGGTCTAAGGTGA-
TAGAGCCTTC) and c-MYC (GTGTTAATTGGGAG-
CACGTGTAGGTC). The DNA-binding sites are written
in bold. In the UTF1 enhancer element, the OCT4-bind-
ing site is written in bold italic and the SOX2-binding site
in bold.
Kinase Assays
Kinase assays were carried out essentially as described 44,45 in
kinase buffer containing 25 mM Tris-HCl, pH 7.5, 5 mM
b-glycerophosphate, 2 mM DTT, 0.1 mM sodium orthovana-
date and 10 mM MgCl2 with or without 200 mM ATP. Three
mg of the recombinant substrates and 0.5 mg of active human
AKT1 protein (Millipore) were incubated for 2 h at 30!C.
Mass spectrometry and data analysis
After the kinase assays proteins were processed for MS analy-
ses as described 46 with the following changes: In-solution diges-
tion was performed with endoproteinases Lys-C, trypsin or
AspN. LC-MS/MS analyses were performed on an EasyLC
nano-HPLC (Proxeon Biosystems) coupled to an LTQ Orbitrap
Elite mass spectrometer (Thermo Scientific) as described.47 For
the analyses, 15 most intense precursor ions were sequentially
fragmented in each scan cycle (90 min, HCD, top15). The MS
data of all experiments were processed using default parameters
of the MaxQuant software version 1.2.2.9.48 Peak lists were
searched against a human target-decoy database (taxonomy id
9606), containing 84946 forward protein sequences and 248
common contaminants, and GST-tagged versions of OCT4,
SOX2 and KLF4. The following criteria were applied for the
database search: Endoproteinases Lys-C, trypsin or AspN were
defined as proteases and 2 missed cleavages were allowed. Carba-
midomethylation of cysteine was set as fixed modification; N-ter-
minal acetylation, oxidation of methionine, and phosphorylation
of serine, threonine and tyrosine were set as variable modifica-
tions. Initial precursor mass tolerance was set to 7 ppm and
20 ppm at the fragment ion level. Identified MS/MS spectra
were further processed by MaxQuant for statistical validation
and quantification of peptides and protein groups. A false discov-
ery rate of 1% was set at the peptide, protein and phosphoryla-
tion site level.
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

7KHHQFDSVXODWLRQRI+53GLGQRWVLJQL¿FDQWO\FKDQJHWKH

+53DFWLYLW\VLQFHHQFDSVXODWLRQHI¿FLHQF\GHWHUPLQHG
        
VLJQL¿FDQWO\ GLIIHU 7DEOH  0RUHRYHU 13V RI ERWK

VKRZHGDQLQLWLDOEXUVWGXULQJWKH¿UVWKZKHQ§RI

VORZHG GRZQ UHDFKLQJ § UHOHDVHZLWKLQ  K7KH

RQO\§ZDVUHOHDVHGDIWHUK)LJXUH%

%DFXORYLUDO2&7H[SUHVVLRQDQGSXUL¿FDWLRQ
      

       

      


LQKLJKLQIHFWLRQHI¿FLHQFLHVDVPRQLWRUHGE\H[SUHVVLRQ
  
       
QXFOHXV RI 6I FHOOV )LJXUH % ZH ¿UVW LVRODWHG WKH
QXFOHLRI6IFHOOV¿YHGD\VSRVWLQIHFWLRQ$IWHUO\VLVRI
WKHQXFOHL*67DI¿QLW\FKURPDWRJUDSK\ZDVSHUIRUPHG
      

WKLVSURWRFRO\LHOGLQJ§PJORISXUL¿HG2&7IURP6I



      
      
      

        

613VLQGXFHGWKHDSSHDUDQFHRIDVSHFL¿F'1$SURWHLQ
       

SUHVHQFHRIDIROGH[FHVVRIXQODEHOHGROLJRQXFOHRWLGH

      

FRQFHQWUDWLRQVGDWDQRWVKRZQLQGLFDWLQJDOHVVHI¿FLHQW
 




       


 
        
  
      
        

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LQ13VZDVHI¿FLHQWO\ LPSRUWHG LQWR WKH¿EUREODVWV DV
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RIWKH¿EUREODVWV
         
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


     
    
LQFOXGLQJWKHXVHRIQRQLQWHJUDWLQJYLUXVHVVLWHVSHFL¿F
  
WUDQVIHFWLRQ>±@$OWKRXJKWKHVHPHWKRGVVLJQL¿FDQWO\
        
       
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   

HQFDSVXODWLRQHI¿FLHQF\DQGUHOHDVHSUR¿OH%RWK613V

UHYHDOHGDPRUHHI¿FLHQWUHOHDVHDQGEHWWHUSUHVHUYDWLRQ


      




  
       
      
     



       
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
KLJK UHSURJUDPPLQJHI¿FLHQF\RI UHWURYLUDO H[SUHVVLRQ

       






      
      
ZHLJKWFKLWRVDQ±N'D6LJPD$OGULFK6W/RXLV
02 DQG WULSRO\SKRVSKDWH 733 0LVWUDO &KHPLFDOV
 
DQG ]HWD SRWHQWLDO ZHUH GHWHUPLQHG XVLQJ D =HWDVL]HU
1DQR =6 GHYLFH 0DOYHUQ ,QVWUXPHQWV +HUUHQEHUJ

       


RQJODVVVOLGHVDQGVXEMHFWHGWR¿HOGHPLVVLRQVFDQQLQJ

&DUO=HLVV5HXWOLQJHQ*HUPDQ\
+RUVHUDGLVKSHUR[LGDVH+53a8PJ6LJPD
       


       
DIIHFW SURWHLQ DFWLYLW\ HQFDSVXODWLRQ HI¿FLHQF\ ((
       
FRQWHQW7RWKLVHQG/13VZHUHFHQWULIXJHGDWJ
IRUPLQEHIRUHXQHQWUDSSHGSURWHLQZDVTXDQWL¿HG


FHQWULIXJDO ¿OWHUV PROHFXODU ZHLJKW FXWRII  N'D
&DUO 5RWK *PE+ .DUOVUXKH *HUPDQ\ IRU  PLQ DW
JEHIRUHWKHQRQHQWUDSSHGSURWHLQZDVTXDQWL¿HG
LQWKHÀRZWKURXJK((EDVHGRQWRWDOSURWHLQFRQWHQWZDV
     
      
+53/13VDQG613VZHUHSXUL¿HGDVGHVFULEHGDERYH
7R P/ RI /13 VXSHUQDWDQW DQG 613 ÀRZWKURXJK
 / RI 1D2+ZHUH DGGHG 6DPSOHVZHUH WKHQ
FHQWULIXJHG DW  J IRU PLQ EHIRUH FKLWRVDQIUHH


$FWLYLW\EDVHGTXDQWL¿FDWLRQRI+53ZDVSHUIRUPHG
DVGHVFULEHG>@%ULHÀ\P/RIP0RIK\GURJHQ
SHUR[LGHLQ0SRWDVVLXPSKRVSKDWHEXIIHUZDVPL[HG

      
QPZDVUHFRUGHGXVLQJD89±9LVVSHFWURSKRWRPHWHU
HYHU\VHFIRUPLQXSRQDGGLWLRQRI/HQ]\PH
FRQWDLQLQJWHVWVROXWLRQ/13VXSHUQDWDQWRU613ÀRZ
  



+53ORDGHG 13V ZHUH SXUL¿HG UHFRQVWLWXWHG LQ P/
GHLRQL]HGZDWHUDQGSODFHGLQVSHFWUDSRUÀRDW$O\]HUV
PROHFXODU ZHLJKW FXWRII  N'D 6SHFWUXP /DEV
%UHGD7KH1HWKHUODQGV13ORDGHGÀRDW$O\]HUVZHUH
       
      
ȝ/RIWKHVDPSOHVZHUHUHPRYHGUHSODFHGZLWKIUHVK
     

2&7H[SUHVVLRQDQGSXUL¿FDWLRQ
      
PHGLD6LJPD$OGULFKVXSSOHPHQWHGZLWKIHWDO
FDOI VHUXP DQG SHQLFLOOLQVWUHSWRP\FLQ  


      


       
LQIHFWLRQ02,RI)LYHGD\VSRVWLQIHFWLRQFHOOVZHUH
KDUYHVWHGE\FHQWULIXJDWLRQDW&IRUPLQDWJ
DQG ZDVKHG WZLFH ZLWK  P/ 3%6 $V UHFRPELQDQW
        
H[WUDFWLRQZDVFRQGXFWHGDVGHVFULEHG>@%ULHÀ\FHOO
SHOOHWVZHUHVXVSHQGHGLQK\SRWRQLFEXIIHUP01D
+(3(6S+P0.&OP0('7$P0
(*7$P0'77DQGP0306)DQGLQFXEDWHGIRU


FHQWULIXJHGDWUSPDW&IRUPLQUHVXVSHQGHGLQ
QXFOHDUO\VLVEXIIHUP01D+(3(6S+P0
.&OP0('7$P0(*7$JO\FHUROP0
'77 DQG LQFXEDWHG DW & IRU  PLQ ZLWK VKDNLQJ
1XFOHDUO\VDWHVZHUH¿OWUDWHGWKURXJKPDQGP
¿OWHUVIROORZHGE\DI¿QLW\FKURPDWRJUDSK\RQJOXWDWKLRQH
      
     
FRQWHQWWKHFROXPQHOXDWHVZHUHSRROHGWRREWDLQD¿QDO
FRQFHQWUDWLRQRIPJP/DQGIUR]HQLQJO\FHURO7KH





    
     
NLW /,&25 %LRVFLHQFH &DPEULGJH 8. %ULHÀ\
UHFRPELQDQW2&7ZDVLQFXEDWHGZLWKORI,5'\H
LQIUDUHGG\HODEHOHGGRXEOHVWUDQGHGROLJRQXFOHRWLGH
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G,G&LQDWRWDOYROXPHRIOIRUPLQDW
576DPSOHVZHUHVHSDUDWHGRQQDWLYHSRO\DFU\ODPLGH
JHOVLQî7ULVERUDWH('7$7KHJHOZDVVFDQQHGE\
LQIUDUHGÀXRUHVFHQFHGHWHFWLRQRQWKH2G\VVH\







       
       
ZHUH SXUL¿HG DQG SURWHLQ FRQWHQW ZDV GHWHUPLQHG E\
ÀXRURPHWU\)/82VWDU2SWLPD%0*/DEWHFK2UWHQEHUJ
*HUPDQ\ ȜH[  QP ȜHP  QP $V D FODVVLFDO
    
     
   

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      

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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      
PRGL¿HG13VZDVSHUIRUPHGDVGHWDLOHGSUHYLRXVO\>@
)RU 13 WUHDWPHQW KXPDQ SULPDU\ ¿EUREODVWV
ZHUH SODWHG LQ ZHOO SODWHV 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         
     

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